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One of the grand challenges in medicine is controlling the balance between bleeding, 
normal blood clot formation and excessive clotting, or thrombosis. The focus of this thesis is on 
the development of microfluidic devices to measure the biochemical network known as 
coagulation under physiological flow conditions and the mass transfer limitations that regulate 
bleeding in hemophilia. Under reaction-limited conditions, blood flow provides a continual 
source of reactants for these reactions. Under transport-limited conditions, blood flow dilutes 
coagulation products so that they do not accumulate near the injury site. Reaction-limited and 
transport-limited regimes were identified in experiments with factors VIII, IX and XI deficient 
plasmas and whole blood as a function of shear rate and tissue factor (TF) concentration. In 
plasma, coagulation was reaction-limited at wall shear rates of less 250 s-1 on high 
concentrations of surface bound TF. Coagulation was transport-limited at shear rate of greater 
than or equal 250 s-1, at low TF, or in the absence of FVIII or FIX. FXI played a role in fibrin 
deposition, morphology and lysis at both low and high TF concentration, whereas it only plays a 
role in low TF under static conditions.  
In whole blood, we found FVIII deficiencies profoundly influence thrombin and fibrin 
formation on TF-rich substrates. In the case of mild FVIII deficiencies (5-30% normal levels) the 
local thrombin concentration is sufficient to promote fibrin formation in and adjacent to platelet 
aggregates. Fibrin formation was not supported by severe (<1%) or moderate (1-5%) 
deficiencies. Treatment with recombinant FVIII normalized fibrin deposition. Whereas, 
treatment with recombinant FVIIa creates a reaction-limited condition where clots form faster 
and are larger than healthy controls, suggesting that this drug could convert a bleeding disorder 
to a thrombotic event at therapeutic doses 	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CHAPTER 1  
INTRODUCTION 
Vertebrates have evolved a robust hemostatic system that keeps blood in its fluid state and 
reacts rapidly at the site of vascular injury by forming a solid plug to mitigate blood loss. The 
formation of a blood clot involves two intertwined processes: platelet adhesion and aggregation 
and coagulation. Platelets adhere to matrix proteins that lie underneath the endothelial cells that 
line all blood vessels. Upon adhesion, platelets become activated and promote the cohesion, or 
aggregation, of other platelets. Simultaneously, a tightly regulated enzymatic network called 
coagulation is initiated on the vessel wall and propagates by means of heterogeneous reactions 
on the platelets’ surface. The end product of coagulation is the enzyme thrombin, which activates 
platelets and catalyzes the polymerization of a fibrous protein called fibrin.  
Fibrin provides mechanical strength to a clot. Dysfunctions in any of these processes can 
cause excessive bleeding or excessive clotting (thrombosis). Excessive bleeding can be caused 
by deficiencies in coagulation proteins, dysfunctions in platelet adhesion and aggregation, or 
anticoagulant and antiplatelet drugs. Thrombosis, which is the leading cause of death in the 
United States, can be caused by the rupture of atherosclerotic plaques in large arteries, stasis in 
blood flow, systemic immune response (e.g. sepsis), and numerous genetic disorders. The focus 
of this thesis is on the development of microfluidic devices to measure coagulation under 
physiological flow and the mass transfer limitations that regulate bleeding in hemophilia under 
flow.  
Coagulation is typically studied under static, no flow conditions, such as in well-plate 
assays. This is the basis of the prothrombin time (PT) and the activated partial thromboplastin 




blood flow on coagulation, and since blood is a moving fluid in vivo, it is important to study it 
under flow in vitro. In this thesis, microfluidic vascular injury models were developed for the 
purpose of fundamental studies of mass transfer limitations in the development of blood clots. 
Specifically, we sought to identify mass transfer limited and reaction limited regimens in 
thrombin generation and fibrin deposition in plasma and whole blood systems.  
Hemophilia is genetic bleeding disorder that results from deficiencies in coagulation 
factors. There are three types of hemophilia; factor VIII (FVIII) deficiency or hemophilia A, FIX 
deficiency or hemophilia B, and FXI deficiency or hemophilia C. Severe forms of hemophilia A 
and B results in spontaneously bleeding in the muscles and joints. The treatment for these 
disorders are expensive recombinant proteins that are administered either on-demand or 
prophylactically. Conventional coagulation assays do not accurately predict bleeding in 
hemophilia, especially in cases of severe disorders. We hypothesize that this is partly due to the 
lack of blood flow in these assays. In this thesis, we apply our microfluidic models to measure 
the bleeding severity and response to treatment in a cohort of individuals with hemophilia. 
One of the grand challenges in medicine is controlling the delicate balance between 
bleeding and excessive clotting. Despite the magnitude of this problem, anticoagulant therapies 
have changed little over the past 50 years. The two major anticoagulant drugs, heparin and 
warfin, are highly non-specific drugs that decrease the entire clotting process. As a result, 
excessive bleeding is a common side effect of these drugs and there is a motivation to identify 
new targets for anticoagulation. One potential target is coagulation factor XI (FXI). Individuals 
with FXI deficiencies, also called hemophilia C, appear to be protected against stroke and venous 




The specific aims of this thesis are: (1) Create a whole blood microfluidic system in which 
the dynamics of fibrin formation and platelet accumulation are measured under physiological 
shear rates. (2) Measure the effect of FVIII deficiencies on fibrin formation, thrombin generation 
and platelet accumulation under flow. (3) Examine the response of individuals with hemophilia 
A to replacement and bypass therapies under venous flow conditions. (4) Design and create a 
plasma based microfluidic flow assay in which coagulation would be initiated from tissue factor 
(TF) bearing surfaces. (5) Define the hemodynamic conditions under which fibrin can form 
under flow on TF-rich substrates. (6) Determine the role of FXI and TF on the initiation and 
propagation of a clot in a microfluidic system. (7) Determine the susceptibility of FXI deficient 
clots to fibrinolysis.  
CHAPTER 2 gives general background information including an overview of platelet 
function, the cell based model of coagulation, and the effects of blood flow on coagulation.  
In CHAPTER 3, we examined the dynamics of thrombus formation in individuals with 
hemophilia A and their response to replacement and bypass therapies under venous flow 
conditions. Fibrin and platelet accumulation were measured in microfluidic flow assays on a TF-
collagen rich surface. In order to aid in the analysis of the experimental data, we used a spatial-
temporal model of thrombus formation on immobilized TF to calculate thrombin generation. 
This model was developed by our collaborators Aaron Fogelson at the University of Utah and 
Karin Leiderman at the University of California, Merced. Our results suggest that FVIII levels of 
greater than 5% can support fibrin formation and that treatment with rFVIIa could potentially 
lead to a prothrombotic state. In CHAPTER 4, we describe a plasma based microfluidic flow 
assay for measuring thrombin generation and fibrin deposition. This method has some 




allowing for the use of frozen plasmas as opposed to freshly drawn blood. The assay uses silica 
beads coated with a TF containing lipid bilayer to simulate the presentation of adherent tissue 
factor bearing microparticles. The results show that fibrin deposition requires perturbations in the 
flow field that protect reactions from dilution by flow under venous and arterial conditions.  
 CHAPTER 5 uses the plasma based microfluidic system developed earlier to investigate 
the relative role of FXI and TF on clot propagation. It incorporates the protein C anticoagulant 
pathway into the assay by adding surface bound thrombomodulin to the procoagulant lipidated 








Blood is an essential fluid for life; it transports nutrients and oxygen to and removes 
waste from tissues, it responds to and eliminates foreign bacteria and viruses, and it rapidly 
responds to injury via the formation of blood clots. In vertebrates, blood is a dense suspension of 
cells in a protein-rich liquid called plasma. The major cells found in blood are biconcave red 
blood cells (6-8 µm; 5-6 × 106/µL), spherical white blood cells (7-15 µm; 4-11 × 103/µL), and 
elliptical platelets (1-3 µm;1.5- 4.0 × 105 /µL). Platelets, in conjunction with a tightly regulated 
enzyme network called coagulation, are the engineers of the circulatory system. They maintain 
vascular patency by repairing injuries by a process called hemostasis. 
 The vascular endothelium maintains blood in its fluid state by presenting an inert surface 
that secretes soluble chemicals that keep platelets in a quiescent state. When vascular injury 
occurs, cells and proteins in the vessel wall initiate a series of events that lead to a stable blood 
clot that prevents blood loss. To ensure that clots form and are localized at the injury site there 
are number of biochemical and biophysical mechanisms that regulate clot formation and growth 
that are described below. A particular focus of this thesis is the mass transfer limitations imposed 
by blood flow on coagulation. Here, we provide an overview of hemostasis, review previous 
work on coagulation under flow and the use of microfluidic devices for studying clot formation.    
2.1 Overview of platelet function  
When a vascular injury occurs in vivo, collagen (types I, III, VI) in the subendothelial 
matrix is exposed to flowing blood (Figure 2.1). At venous wall shear rates (50–250 s-1) platelets 




At arterial shear rates (500–2000 s-1), the platelets must first roll on von Willebrand Factor 
(vWF) via the GP1b receptor prior to arrest and firm adhesion to collagen [4]. Once the platelets 
have adhered to the collagen surface, they become activated, which means they release their 
calcium stores, dump out the contents of their alpha granules containing fibronectin and vWF 
and dense granules containing adenosine diphosphate (ADP), adenosine triphosphate (ATP) and 
ionized calcium, and the integrins α2β1 and αIIbβ3 shift towards their activated state. In addition, 
activated platelets expose the phospholipid phosphatidylserine (PS) on their surfaces, which 
serve as binding sites for membrane-bound coagulation factors [5]. These surfaces help to 
augment the coagulation process by providing initiation sites for the coagulation reactions. 
Activation is not an all-or-nothing response. The number of bound receptors and local 
concentration of platelet agonists (collagen, thrombin, ADP, thromboxane), and inhibitors (nitric 
oxide, prostacyline) determine the degree of activation.  
Platelets adhered to the subendothelium promote aggregation with other platelets that are 
flowing by the nascent clot in a two-step process. First, plasma vWF bound to the platelet surface 
via αIIbβ3 enable new platelets to bind and role on adhered platelets via GP1b. Next, once new 
platelets are in close contact with adhered platelets they can be activated by soluble agonists 
(thrombin, ADP, thromboxane A2) and by GP1b outside-in signaling. The activated platelets 
firmly adhere to other platelets through αIIbβ3-fibrin(ogen). This process repeats itself to add 
futher layers of platelets. As the clot grows further from the surface, there is evidence that 
platelets are less activated and thus less likely to support further aggregation.  
2.2 Overview of coagulation 






Figure 2.1. Key receptors responsible for platelet adhesion to collagen (blue lines) and VWF 
(black ball and strings) and aggregation. EC = endothelial cell. Adapted from Neeves and 
Fogelson, Annual Reviews of Fluid Mechanics, in press.  
classic “waterfall” model, which was first introduced in the 1960’s. This model implies a set of 
sequential homogenous reactions that initiate via the intrinsic (contact) or extrinsic (tissue factor) 
pathways that coalesce at the generation of FXa. However, most coagulation reactions are 
heterogeneous, and while interdependent, can occur simultaneously. In this work, we will use the 
cell-based model to describe coagulation, in which the reactions require the participation of two 
types of cells, platelets and tissue factor (TF)-bearing cells. In the cell-based model, coagulation 
has three steps; initiation, amplification and propagation [6]. In this thesis, I will abbreviate 
coagulation factors as FX and FXa, which is read factor X and activated factor X, where the 
former is the zymogen and the latter the enzyme. 
2.2.1 Initiation phase 
The initiation step starts when the vascular wall is damaged and extravascular tissue 
factor (TF) or vascular cells that express TF are exposed to the blood [7]. TF binds FVIIa, which 
circulates in the plasma. This forms the complex TF:FVIIa, which is cell bound, and converts 




small amounts of prothrombin (FII) to thrombin (FIIa) (Figure 2.2). Platelets adherent to 
collagen are also important contributors to this phase because they secrete FV from their alpha-




2.2.2 Amplification phase 
Once thrombin has been produced on the TF bearing cell, the thrombin activates more 
platelets that are flowing in the blood through the protease-activated receptors (PAR1 and 
PAR4). Outside-in signaling through the PARs and other platelet receptors leads to exposure of 
phosphatidylserine (PS), which acts as a binding site for prothrombinase. Therefore the 
Figure 2.2. Cell based model of coagulation. Adapted from Neeves and Fogelson, Annual 




thrombin-activated platelets provide more surface area for the coagulation reactions to initiate 
and amplify the production of more thrombin by activating FV, FVIII, and also FXI which are all 
residing on or near the platelet surface. Thrombin production is an example of a positive feed 
back loop in which one enzyme produced in one step promotes the production of other enzymes 
and itself. 
2.2.3 Propagation phase and fibrin polymerization 
This phase occurs when thrombin concentrations are sufficient enough to convert the 
plasma protein fibrinogen into fibrin monomers that can polymerize to form the biopolymer 
fibrin. This phase occurs most effectively on the platelet because its surface is specialized 
enough to coordinate the assembly of the tenase (FIXa:FVIIIa) and prothrombinase (FXa:FVa) 
complexes, and it produces enough surface area for huge thrombin production. Once enough 
thrombin is produced, it starts fibrin polymerization. Thrombin cleaves short peptide fragments 
(fibrinopeptides A and B) to expose a pair of binding sites on the central C domain of the 
fibrinogen molecule, which binds to other complimentary sites of other fibrin molecules. This is 
the fibrin extension, and then, linear polymerization leads to lateral aggregation, which forms 
branch points, and finally a fibrin gel (Figure 2.3).  
2.3 FVIII and hemophilia A 
 FVIII circulates in its inactive form bound to vWF. vWF acts as a chaperone that helps 
to localize FVIII to an injury site and protects it from degradation in the plasma. During 
coagulation, FXa or thrombin cleaves FVIII to form FVIIIa. FVIIIa forms the FVIIIa:FIXa 
tenase complex (Xase), which assembles on anionic phospholipid surfaces. The Xase complex 







The role of FVIIIa is to serve as a cofactor for factor IXa and increase the catalytic rate constant 
for the activation of FX and prothrombin by several orders of magnitude [8]. 
Hemophilia A is an X-chromosome-linked disease that results in deficiencies in factor 
VIII [9]. The frequency and the intensity of bleeding in hemophilia A depends on the 
concentration of FVIII in plasma. The frequency of the disorder is 1 in 5000 to 10000 male births 
[10].  50-60% of individuals with hemophilia A have severe deficiencies (<1% normal levels), 
which are characterized by frequent spontaneous bleeding in muscles, joints and internal organs. 
25-30% of individuals have moderate deficiencies (1-5% normal levels) and bleeding occurs 




usually after minor trauma. 15-20% of individuals have mild deficiencies (5-30% normal levels) 
and only bleed after major trauma, or the do not bleed at all. The therapies for hemophilia A 
include using FVIII replacement therapies, bypass therapies (FVIIa or prothrombin complex) and 
gene therapy.  Previous work with human blood conducted in in vitro flow assays show that 
severe FVIII deficiencies (<1% of normal level) result in reduced fibrin formation and smaller 
blood clots [11] [12].  
Flow assays on animal derived subendothelium that contain TF show a reduction in 
thrombus size and fibrin deposition for severe FVIII deficiencies at a shear rate of 650 s-1. Also, 
FVIII null mice have inhibited thrombi formation on collagen-TF substrates at venous shear 
rates, but not arterial shear rates [13]. These studies have shown that FVIII plays an important 
role in thrombus formation in severe hemophilia cases. In this thesis work, we go further to 
explore how mild (1-5%), and moderate (5-30%) FVIII deficiencies affect thrombus formation 
under flow. 
2.4 Factor XI and hemophilia C  
FXI is probably the most recent of the addition to the vertebrate plasma coagulation 
network, most likely making its appearance in the marsupial mammals [14]. In humans, FXI 
deficiency or hemophilia C, is an autosomal recessive trait that is present in 1 in 100,000 
individuals worldwide and at a higher incidence of 1:12 in Ashkenazi Jews. Severe FXI 
deficiency is associated with a reduced incidence of ischemic stroke, although the mechanism for 
this observation is currently debated [15]. There is renewed interest in FXI based on recent 
research on population-based studies and animal models [16], which indicates evidence that FXI 
deficiency may offer a protection against deep vein thrombosis and stroke [17]. Since 




clotting is still the leading cause of death in the United States, FXI is being investigated as a 
potential target for anticoagulation. FXI can be converted to FXIa in several ways as outlined 
below. Each of these mechanisms is a potential drug target. 
 2.4.1 Activation of FXI by FXIIa 
Factor XI can be activated by factor XIIa via the intrinsic pathway. However, the work of 
Gailani and colleagues shows that mice lacking FXI and FXII on a substrate of low TF 
expression are still viable with activation of FIX to induce clot formation [18]. In addition, the 
fact that the absence of a bleeding disorder in patients with a FXII deficiency suggests that FXI 
can be activated by an alternative mechanism other that FXII [19].  
2.4.2 Platelet interaction with FXI 
Platelets have been shown to enhance FXII-independent FXI activation by thrombin and 
the platelet receptor apolipoprotein E receptor 2 (ApoER2, LRP8) as a platelet receptor for FXI. 
There is a growing evidence to support the fact that platelets affect the behavior of FXI under 
flow [20]. When FXII deficient whole blood was perfused over collagen, and platelets deposited, 
aggregated and fibrin was formed. However, when a FXI specific antibody that blocks the 
activation of FXI was introduced into the system, the formation of fibrin stopped [16]. This 
suggests that platelets might influence the activation of FXI.  
2.4.3 Thrombin activation of FXI 
The most convincing method of activating FXI to date is probably by thrombin. This 







This thrombin in turn activates more FXI, which leads to a large-scale production of 
thrombin, even in the absence of FXII [14]. Apart from thrombin production, FXI has been 
shown to enhance fibrin generation and also inhibit fibrinolysis, which means it helps to 
strengthen and reinforce a fibrin mesh, so that it is not lysed or degraded [21]. These results were 
however obtained from a static system. These studies give a good basis and foundation for this 
thesis work, which will mostly be conducted at physiological flow conditions, to simulate in vivo 
blood flow. 
2.5 Biochemical regulation of coagulation  
A balance between procoagulant and anticoagulant pathways is necessary for hemostasis. 
There are two main biochemical mechanisms that attenuate procoagulant processes: the serine 




protease inhibitors and the protein C pathway. The serine protease inhibitors, also called serpins, 
function by forming a stable stoichiometric 1:1 complex with target coagulation proteases and 
neutralizing them [22]. Examples of serpins include antithrombin III and tissue factor pathway 
inhibitor (TFPI). Antithrombin III is a glycoprotein produced by the liver and consists of 432 
amino acids. Its activity is enhanced when it interacts with the anticoagulant drug heparin, which 
facilitates its binding to thrombin, factor IXa and Xa [23].  
The protein C pathway is activated when thrombin binds to thrombomodulin (TM) [24]. 
TM affects the biological function of thrombin by changing its activity. Then, the thrombin:TM 
complex functions by cleaving the plasma zymogen, protein C, which leads to the production of 
activated protein C (APC). APC then interacts with protein S on membrane surface to inactivate 
factor Va and VIIIa, which in turn diminishes the production of Xa and ultimately leads to 
decreased thrombin production. 
2.6 Mass transfer regulation of coagulation 
Coagulation is kinetically limited by anticoagulation pathways, but is also regulated by 
mass transfer limitations connected with the transport of the zymogens to and enzymes away 
from the injury site, physical inhibition of TF by platelet and by hindered transport of 
coagulation proteins in the interstitial spaces of clots.  
2.6.1 Mass transfer regulation of surface coagulation reactions and fibrin polymerization 
Three enzyme complexes–TF:FVIIa, FIXa:FVIIIa, FXa:FVa–assemble on SE and 
activated platelet surfaces and are regulated, in part, by mass transfer limitations. Blood flow can 
either promote or inhibit these surface reactions depending on the shear rate. FXa production by 




increasing shear rate [25]. In contrast, FXa production is reaction-limited (its flux is constant) for 
shear rates greater than 600 s-1. When both TF:FVIIa and FVIIIa:FIXa are present, their 
combined FXa production is transport-limited from 57 to 1300 s-1 [26]. Thus, blood flow 
enhances the initiation of coagulation for all physiological shear rates provided normal 
concentrations of FVIII, FIX and FX are present. Thrombin production by prothrombinase in a 
phospholipid bilayer is reaction-limited for shear rates 100–1000s-1 [27]. Flow acts as an 
inhibitor by diluting thrombin and thus localizing high thrombin concentrations to the immediate 
vicinity of a clot.  
Regardless of the shear rate, a threshold TF surface density is necessary to initiate 
coagulation. This threshold behavior was first predicted by simulations of clot formation on 
immobilized TF [5] and confirmed by in vitro blood flow assays over 175 µm spots containing 
TF and collagen [28]. The threshold TF density required to initiate coagulation under flow 
increases three-fold as shear rate increases from 100–1000 s-1 to A certain injury size is also 
necessary to initiate coagulation both statically and under flow on immobilized TF in lipid 
bilayers [29, 30]. Presumably vessel walls are always subject to some degree of disruption, and 
thus TF exposure. The thresholds likely ensure that coagulation is initiated only on injuries that 
are sufficiently large or deep to expose high densities of TF.  
Fibrin polymerization can be either transport or reaction-limited depending on thrombin 
wall flux and the shear rate [31]. A kinetic model of fibrin gel formation predicts two regimes of 
growth depending on the shear rate and gel permeability [32]. At low shear rates, growth is 
limited by the transport of thrombin from the procoagulant surface to the surface of the gel. The 
rate of thrombin transport is determined by the hydraulic permeability, which varies over three 




limited by dilution of fibrin polymers before they can reach a gelation concentration. This agrees 
with experiments in purified systems that show little or no fibrin gelation at wall shear rate 100 s-
1 on flat substrates even at high thrombin concentration (1 µM). Surfaces with a micron-scale 
roughness provide some protection of polymerization products from dilution by flow. For 
example, 800 nm TF-coated beads support the initiation of fibrin formation at 1000 s-1 at 
sufficiently high TF surface density [34], but the gel's ultimate growth into a channel is limited to 
10-15 µm at 100 s-1 which is similar to predicted gels heights in computational models [35]. 
2.6.2 Physical inhibition of tissue factor by platelets 
Most coagulation experiments are performed with purified protein solutions or plasma, 
ignoring the contribution of platelets to regulating coagulation. Platelets support coagulation by 
providing a surface for the assembly of tenase and prothrombinase, as well as binding sites for 
other coagulation proteins. Platelets inhibit coagulation by physically impeding access to 
TF:FVIIa. This mechanism was first hypothesized from simulations of hemophilia A and B 
(FVIII and FIX deficiency) that did not show a reduction in thrombin generation in the absence 
of some sort of physical inhibition of TF:FVIIa [5].  It is supported by experiments under static 
conditions that show that FXa flux through a platelet plug is 1000-fold less than FXa flux 
through fibrin [36]. Experiments performed under flow show that, at high TF concentrations, 
severe FVIII deficiencies  (<1%  normal levels) do not affect fibrin polymerization in plasma, 
but lead to significant reductions in whole blood [37, 38]. 
 The tension between the platelets' pro and anti-coagulant roles underlies the TF-
threshold for initiating coagulation [35], and the ability to make near-normal amounts of 
thrombin with 10% normal platelet concentrations in simulations [5]. Experiments with blood 




fibrinopeptide A (FPA) generation (a marker for fibrin monomer production) decreased with 
increasing shear rate [39]. Fibrin deposition was independent of platelet adhesion below 100 s-1 
but positively correlated to platelet count in patients with low platelet counts (thrombocytopenia) 
at 650 s-1. In contrast, FPA levels were not correlated to platelet count. This suggests that 
thrombin was being produced, but fibrin monomers and oligomers were not able to form fibers 
before being washed away by the flow. 
2.6.3 Hindered transport through the interstitial spaces of clots 
Recent evidence suggests that, even beyond the role of adherent platelets in blocking 
access to TF, the formation of platelet aggregates and fibrin gel inhibits solute transport in the 
clot and this contributes to the regulation of clot growth.  The clot takes on the character of a 
spatially heterogeneous porous medium, and fluid and solute transport through it are reduced 
compared to their transport to and from the vessel wall during clot initiation. 
Computational models, in which transport coefficients decrease with increased bound 
platelet density, predict that hindered transport of coagulation zymogens and enzymes results in 
smaller, more dense clots [40].  Hindered transport confines activating complexes to a dense 
platelet core, and reduces the supply of substrates to them.  For example, in late stages of clot 
growth, the prothrombinase complex is concentrated on platelets near the vessel wall.  In order 
for prothrombin to reach this prothrombinase, it must be transported through a shell of 
aggregated platelets that do not contain prothrombinase. As a result, prothrombin penetrates only 
deeply enough to reach prothrombinase in a thin strip several microns from the edge of the clot, 
and only there does thrombin production continue.  Consequently thrombin production decreases 




These computational models agree qualitatively with the core-shell structure of clots 
formed in the laser-injury animal model of vascular injury [40]. The core consists of densely-
packed, highly-activated platelets surrounded by a more porous shell of less activated platelets. 
Movement of solutes into and out of the core is limited [41].  Computational studies [42] suggest 
another possible mechanism of hindered transport that involves a fibrin cap formed on the 
luminal surface of a clot that prevents platelets from interacting with regions of high thrombin 
concentration in the clot core. 
2.7 Microfluidic devices for measuring platelet function and coagulation 
The past decade has seen numerous reports of microfluidic devices for the study of flow 
dependent thrombus formation. The use of microfluidics in hemostasis is based upon a large 
body of work performed in what are generically called flow assays [43-45]. Flow assays include 
annular and parallel plate chambers. These have been indispensible tools for measuring shear 
stress dependent receptor-ligand dynamics and shear rate dependent coagulation and fibrin 
formation. 
The shear stress [τ (force/area)] represents the force experienced by the endothelial wall 
and adherent blood cells due to flowing blood. The shear rate [γ (1/time)] represents the velocity 
gradient near the wall and is proportional to the flow rate through a channel. The shear stress is 
related to the shear rate through the viscosity [τ = µ × γ], which in the case of blood depends both 
on the fluid velocity and the size of the vessel (Table 2.1). The shear rate is lowest in veins (20-
200 s-1) and higher in arterioles (500-1600 s-1) and large arteries (300-800 s-1).  
There are limitations to applying conventional flow assays beyond the research setting. 




low with typically only one condition (shear rate, substrate) per chamber. Third, the geometries 
of these chambers are usually straight channels that result in a unidirectional laminar flow. 







As such, these chambers do not mimic the complex fluid dynamics that give rise to important 
biophysical mechanisms of platelet function and coagulation. Microfluidic technology addresses 
each of these limitations and has opened new lines of research in shear dependent phenomena 
related to thrombus growth. A review of a few key studies of microfluidic applications in 
hemostasis demonstrates the advantages of this approach compared to conventional flow assay. 
For a broader background on microfluidic device fabrication and applications in cell adhesion, 
there are two excellent review articles by Westein and Prabhakarpandian [46, 47].  
One feature of microfluidic devices is that it is easy to incorporate many channels, and 
thus, observe many shear rates simultaneously using a small volume of blood. An elegant 
example of this parallelization is an eight-channel microfluidic device designed by Gutierrez 
and colleagues [48]. The salient feature of this device is that blood flows through each channel 
Vessel Shear rate (per second) 
Veins 20-200 
Arterioles 500-1,600 
Stenotic vessels 800-10,000 




(24 µm x 200 µm) at a different shear rate, providing a 100-fold range of shear rates using just 
15 µL of whole blood in a 4 min assay. The low volume requirement lends itself to studies with 
genetically engineered animal models without having to sacrifice the animal.  
A second feature of microfluidic devices is the ability to combine them with 
micropatterning techniques to define small, focal patches of prothrombotic substrates. Neeves 
and colleagues described a device consisting of a 100 µm strip of collagen patterned on a glass 
substrate perpendicular to an array of 13 microfluidic channels (80 µm x 100 µm) [49]. This 
collagen “injury” mimics the focal nature of animal models like the laser injury model, 
eliminates issues regarding upstream activation of platelets, and simplifies image quantification. 
Additionally, unlike animal models, the shear stress in flow assays is a user-defined 
parameter. This feature has been used to subject thrombi to high shear stress challenges as a 
measure of stability. For example, in a dyslipidemia mouse model (LDLR-/-), mice deficient in 
the contact dependent platelet receptor sema4D produced thrombi that were mechanically less 
stable at high shear rates (10,000 s-1) compared to mice with the receptor [50]. Devices based on 
this model have been applied in several studies of genetically modified mice as a 
complementary measurement of platelet function to in vivo injury models [51-53].  
With a growing appreciation of the profound role that flow plays in coagulation, 
anticoagulation and fibrin formation [54-56], there is a mounting need to integrate these 
pathways into in vitro flow assays.  One approach is flowing plasma or whole blood over pro- 
and anticoagulant proteins in immobilized in lipid bilayers [27, 29, 57]. Ismagilov and 
colleagues use this approach in a series of studies to control the spatial presentation of lipidated 




studies is the description of the critical size and surface concentration of TF necessary to initiate 
thrombin generation under flow. An alternative approach is introducing platelet agonists and/or 
coagulation zymogens/enzymes at a known rate from one wall of a channel [28, 31]. For 
example, a membrane microfluidic device was used to define the conditions under which fibrin 
fibers can form under flow in a purified system of thrombin and fibrinogen [28].  
In a whole blood system, Diamond and colleagues used a microarray tool to co-pattern 
collagen and TF in a parallel plate flow chamber [59]. They reported a distinct threshold surface 
concentration necessary to induce fibrin formation at shear rates of 100-1000 s-1. This collagen-
TF co-patterning approach has since been modified to microfluidic formats [60-62]. In that, 
rather then relying on physical adsorption, liposomal TF is conjugated to fibrillar type 1 
collagen using a streptavidin-biotin linkage [60]. This surface was used to measure the role of 
fibrin in stabilizing thrombi under normal and pathological shear rates. In another model, a side 
channel filled with collagen-TF was used to measure the permeability and retraction of thrombi 
[62]. From this study, a novel biophysical mechanism was reported where the cessation of flow 
results enhances platelet retraction. Under flow, soluble platelet agonists are diluted; while 
under stasis they accumulate, promote outside-in signaling through ADP and thromboxane 
receptors, ultimately leading to retraction.  
Since the publication of these studies, there has been an explosion of devices using 
microfluidic technology to study platelet and endothelial function [46, 47, 62]. There are now 
several commercial turn-key microfluidic systems available for studying cell adhesion under 
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3.1. Abstract 
Clinical evidence suggests that individuals with factor VIII (FVIII) deficiency 
(hemophilia A) are protected against venous thrombosis, but treatment with recombinant proteins 
can increase their risk for thrombosis. In this study we examined the dynamics of thrombus 
formation in individuals with hemophilia A and their response to replacement and bypass 
therapies under venous flow conditions. Fibrin and platelet accumulation were measured in 
microfluidic flow assays on a TF-rich surface at a shear rate of 100 s-1. Thrombin generation was 
calculated with a computational spatial-temporal model of thrombus formation. Mild FVIII 
deficiencies (5-30% normal levels) could support fibrin fiber formation, while severe (<1%) and 
moderate (1-5%) deficiencies could not. Based on these experimental observations, 
computational calculations estimate an average thrombin concentration of ~10 nM is necessary 
to support fibrin formation under flow. There was no difference in fibrin formation between 
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severe and moderate deficiencies, but platelet aggregate size was significantly larger for 
moderate deficiencies.  
Computational calculations estimate that the local thrombin concentration in moderate 
deficiencies is high enough to induce platelet activation (>1 nM), but too low to support fibrin 
formation (<10 nM). In the absence of platelets, fibrin formation was not supported even at 
normal FVIII levels, suggesting platelet adhesion is necessary for fibrin formation. Individuals 
treated by replacement therapy, recombinant FVIII, showed normalized fibrin formation. 
Individuals treated with bypass therapy, recombinant FVIIa, had a reduced lag time in fibrin 
formation, as well as elevated fibrin accumulation compared to healthy controls. Treatment of 
rFVIIa, but not rFVIII, resulted in significant changes in fibrin dynamics that could lead to a 
prothrombotic state.  
3.2. Introduction 
Hemophilia A (HA) is an X-linked genetic disorder that results in deficiencies of 
coagulation factor VIII (FVIII). The primary clinical manifestation of FVIII deficiencies is 
bleeding in the joints and muscles. Individuals with FVIII deficiencies are typically treated by 
replacement or bypass therapies. Replacement therapies involve injection of FVIII concentrates 
from plasma or recombinant FVIII (rFVIII) expressed in mammalian cell lines. Bypass therapies, 
which are used in cases where an individual has developed inhibitors against FVIII, include 
activated prothrombin complex concentrates (aPCC) and recombinant factor VIIa (rFVIIa). 
These drugs “bypass” the generation of factor Xa (FXa) via the FVIIIa:FIXa complex by 
promoting thrombin formation through elevating the plasma concentration of prothrombin and 
FXa (aPCC) or rFVIIa. Venous thrombosis appears to be rare in individuals with FVIII 




review of all reported cases of non-catheter induced venous thrombosis in hemophilia, the most 
cited risk for thrombosis is treatment with bypassing agents [67]. The precise mechanisms of 
venous thrombosis has yet to be determined, however recent evidence suggests that tissue factor 
(TF) derived from endothelial adhered blood cells and microparticles likely plays a central role 
[68].  
Previous in vitro flow assays studies with human blood show that severe FVIII 
deficiencies (<1% normal levels) or inhibition of FVIII results in smaller thrombi and reduced 
fibrin formation on collagen substrates at venous shear rates, but not arterial shear rates [11, 12]. 
Flow assays on animal derived subendothelium that contain TF also show a reduction in 
thrombus size and fibrin deposition for severe FVIII deficiencies at a shear rate of 650 s-1 [69]. 
Similarly, FVIII null mice have inhibited thrombi formation on collagen-TF substrates at venous 
shear rates, but not at arterial shear rates [13]. In the ferric chloride model, FVIII null mice 
formed unstable thrombi that could not occlude venules [70]. In the laser injury model, FVIII 
null mice formed smaller and less stable thrombi than wild type controls in venules [71]. These 
studies indicate that FVIII plays an important role in thrombus growth at venous shear stresses. 
However, these studies have only considered the absence of FVIII or FVIII levels of <1%, and 
therefore it is unknown how mild (1-5%) and moderate (5-30%) FVIII deficiencies affect 
thrombus formation under flow.  
In this study, whole blood from a cohort of individuals with a wide range of FVIII levels 
(<1% to 26%) was perfused in microfluidic flow assays over collagen-TF substrates at venous 
flow conditions (100 s-1). We also measured the effect of treatment with recombinant FVIII 
(rFVIII) and recombinant factor VIIa (rFVIIa) on thrombus formation. In order to aid in the 




immobilized TF to calculate thrombin generation [39]. Our results suggest that FVIII levels of 
>5% can support fibrin formation and that treatment with rFVIIa could potentially lead to a 
prothrombotic state. 
3.3 Materials and Methods 
3.3.1 Materials 
L-α-phosphatidylcholine (PC) and L-α-phosphatidylserine (PS) were purchased from 
Avanti Polar Lipids (Alabaster, AL, USA). Texas red 1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine (DHPE) was purchased from Invitrogen (Carlsbad, CA, USA). Lipidated 
and non-lipidated recombinant human tissue factor, recombinant double-chain tissue 
plasminogen activator, and an IMUBIND tissue factor ELISA Test Kit were purchased from 
American Diagnostica. Bio-Beads SM-2 were purchased from BioRad Laboratories (Hercules, 
CA, USA). Sodium deoxycholate was purchased from CalBiochem (Gibbstown, NJ, USA). 
Fibrillar collagen type 1 from equine tendon was from Chronolog Corp (Havertown, PA, USA). 
Alexa Fluor 488 protein labeling kit (Invitrogen, Carlsbad, CA, USA) was used to label 
fibrinogen according to the manufacturer’s instruction. Pacific Blue anti-human CD41 
(Biolegend, San Diego, CA, USA) was used to label platelets. Normal pooled plasma and FVIII 
deficient plasma was purchased from George King Bio-medical (Overland Park, KS). 16 well 
FAST slide incubation chambers were purchased from Whatman Inc. (Piscataway, NJ, USA) and 
used to pattern collagen and tissue factor on glass slides. Polydimethylsiloxane (PDMS) was 
used to fabricate microfluidic devices (Sylgard 184, Dow Corning, USA). HEPES buffered 
saline (HBS, 20 mM HEPES, 150 mM NaCl, pH 7.4) was made in house. All other reagents 




3.3.2 Preparation of lipidated tissue factor 
TF was incorporated into liposomes using the method described by Smith and Morrissey 
[72]. Briefly, PC, PS and DHPE lipids stored in chloroform were dried under vacuum for one 
hour at an 80:19:1 molar ratio. The dried lipid film was then resuspended in 1 mL of 20 mM 
sodium deoxycholate in HBS, and allowed to hydrate for one hour at room temperature. 
Recombinant tissue factor (TF) was then added to the lipid mixture and incubated for 10 min. 
(8700:1 lipid:TF). Next, 50 mg of Bio-Beads slurry was added to the TF mixture to remove the 
sodium deoxycholate and agitated for 90 min. An additional 350 mg of Bio-Beads slurry was 
then added to the same mixture and agitated for another 90 min. Finally, the beads were allowed 
to settle, and the supernatant of liposomal TF was collected. The concentration of the lipidated 
TF was 461 nM as determined by ELISA. 
3.3.3 Patterning of prothrombotic substrates 
Clean glass slides were inserted into incubation chambers with 16 wells with dimensions 
of 7 mm x 7 mm x 4 mm (L x W x D). Three adjacent wells were used to pattern patches of 
collagen and TF. First, 100 µL of 100 µg/mL type 1 fibrillar collagen was incubated in a well for 
one hour at room temperature. Following incubation, the collagen solution was removed and 
replaced with 100 µL of lipidated TF and allowed to incubate for 30 min. at room temperature. 
The stock lipidated TF (461 nM) was diluted to give surface concentrations of 0.23, 2.3 and 23 
fmol TF/cm2. While the slides were still in the incubation chambers, they were rinsed three times 
with HEPES buffered saline (HBS). Finally, the entire slide was blocked in 5 mg/mL bovine 





3.3.4 Subject recruitment and blood collection 
Subjects were recruited at the Hemophilia and Thrombosis Center of the University of 
Colorado Denver. The study and consent process received Institutional Review Board (IRB) 
approval from the University of Colorado Anschutz Medical Campus, and written informed 
consent was obtained for all participants. For participants under the age of 18, written informed 
consent was obtained from a parent or guardian. Participants consented to have information such 
as age, race and ethnicity shared in publications of research results. Phlebotomy was conducted 
in accordance with the Declaration of Helsinki and under the Colorado Multiple IRB. The 
treatment of patients with replacement and bypassing therapies was clinically indicated and 
independent of this study. Drs. Wang and Di Paola were responsible for providing treatment. 
Whole blood was collected via venipuncture into 3.2% sodium citrate.  
3.3.5 Laboratory phenotype of hemophilia A 
Plasma FVIII activity levels were measured with a standard one-stage clotting assay 
(FVIII:C) using a ST4 coagulometer (Diagnostica Stago). Patient whole blood was centrifuged 
for 15 minutes at 4 °C and 2500 × g, and the plasma supernatant was then centrifuged for an 
additional 15 minutes at the same settings to remove residual platelets. Normal pooled plasma 
(NPP) was obtained from a commercial source (George King Bio-Medical, Overland Park, KS). 
Samples were categorized by the percent of FVIII compared to NPP: severe (<1% FVIII), 
moderate (1–5%), mild (5–30%), and control (>50%).  
3.3.6 Replacement therapy with rFVIII  
Four patients (referred to as patients 1-4) with severe hemophilia were treated with 




the microfluidic flow assay. Patient 1 is a 13 year old Caucasian male who received 41 IU/kg of 
rFVIII (Kogenate, Bayer). Patient 2 is a 19 year old Hispanic male who received 50 IU/kg of 
rFVIII (Helixate, CSL Behring). Patient 3 is a 13 year old Caucasian male who received 27 
IU/kg of rFVIII (Kogenate, Bayer). Patient 4 is a 4 year old Caucasian male who received 24 
IU/kg or rFVIII (Advate, Baxter). 
3.3.7 Bypass therapy with rFVIIa  
Two patients (referred to as patients 5 and 6) with severe hemophilia and history of high 
inhibitors were treated with rFVIIa and their pre and post (30 minutes after infusion) samples 
were drawn and evaluated in the microfluidic flow assay. Patient 5 is a Caucasian male with an 
inhibitor titer of 7.2 Bethesda Units (BU). Patient 6 is a Hispanic male who had a titer of 3.1 BU. 
Both patients received a dose of 90 µg/kg of rFVIIa (NovoSeven, Novo Nordisk).  
3.3.8 Microfluidic flow assays 
The design and operation of the microfluidic flow assay followed previous protocols with 
a few minor changes [73]. A device consisting of three channels with a height of 100 µm and a 
width of 500 µm was reversibly vacuum bonded to a patterned collagen-TF substrate on a glass 
slide. The flow rate was set in a syringe pump to achieve the desired wall shear rate. Blood was 
incubated for 10 min. with a non-function blocking Pacific Blue antihuman CD41 antibody. 
Exogenous AlexaFluor488 labeled human fibrinogen was added to the whole blood at a molar 
ratio of 100:1 (plasma:labeled) assuming a fibrinogen plasma concentration of 3 mg/mL. Whole 
blood was recalcified with 7.5 mM CaCl2 immediately before the assays. Whole blood or plasma 
(normal pooled or FVIII deficient) was perfused through the channels for 5 min. at a wall shear 




upstream edge of the collagen-TF patch using an inverted fluorescence microscope (40X, NA 
0.6, Olympus IX81) equipped with a 16-bit CCD camera (Orca-R2, Hamamatsu). An image was 
captured in each channel every 10 sec. over the duration of the experiment. After whole blood 
perfusion, a wash buffer (HBS, 2mM CaCl2, 1 U/mL heparin) was perfused through the channel 
for 5 min. at a shear rate of 100 s-1 and then samples were prepared for D-Dimer measurements 
or scanning electron microscopy. 
3.3.9 D-dimer assay 
A plasmin solution (288 µg/ml in HBS) was perfused through the microfluidic channel at 
a flow rate of 5 µL/min for 10 minutes, and then flow was stopped for 10 minutes to allow for 
any remaining fibrin to be digested. The plasmin solution was collected from the device and snap 
frozen and stored at -70° C. D-dimer levels were measured by ELISA (American Diagnostica) 
according to the manufacturers instructions at a dilution factor of 1:10 (digested fibrin:diluent).   
3.3.10 Image analysis 
Platelet aggregate area and surface coverage was calculated using previously described 
custom image analysis routines [73]. For fibrin density, a disk structuring element decomposition 
was used to estimate the background fluorescence [74]. The background was subtracted from the 
raw image and the integrated fluorescence (sum of each pixel) of the entire image was 
normalized by the image area.  
3.3.11 Scanning electron microscopy 
Samples were prepared as previously described [31]. Samples were imaged by scanning 





3.3.12 Spatial-temporal model of thrombus formation 
The two-dimensional spatial-temporal model consists of partial differential equations for 
the concentration of platelets and coagulation chemicals that evolve under flow [9]. The 
differential equations, physical properties and rate constants are given in the Supporting 
Information attached to this thesis work. The rectangular domain in which the equations are 
solved represents a segment of blood vessel with 60 µm height, 240 µm length, and wall shear 
rate of 100 s-1. A 90 µm portion of the bottom wall is considered injured, exposing 
subendothelium-bound TF and collagen to the flowing blood. The exposed TF initiates 
coagulation reactions and the collagen allows platelets to adhere. Platelets activated by thrombin 
via coagulation also adhere at the injury site and a porous thrombus forms. The porous thrombus 
physically hinders the flow of plasma within the thrombus relative to the free stream velocity 
outside of the thrombus.  
3.3.13 Statistical analysis 
Correlation coefficients were calculated using the Spearman statistic. Kruskal-Wallis 
ANOVA was used to determine differences (p<0.01) between clinical groups, followed by a post 
hoc Tukey’s honestly significant difference test to determine differences between pairs. The 
Mann-Whitney U-test was used to determine differences (p<0.01) between fibrin dynamics 
metrics before and after replacement and bypassing treatments.  
3.4 Results  
3.4.1 Sensitivity of fibrin accumulation to surface TF concentration and shear rate 
In order to model venous thrombosis, we determined the TF surface concentration that 




100 s-1 over collagen-lipid surfaces with a TF surface concentration of 0, 0.23, 2.3 and 23 fmol 
TF/cm2 (Fig. S1). The total lipid concentration and collagen concentration (100 µg/mL) was held 
constant. There was no difference in fibrin accumulation between no TF and 0.23 fmol TF/cm2, 
demonstrating that this concentration was below the threshold level needed to induce fibrin 
formation in agreement with previous results [28]. At 2.3 fmol TF/cm2 there was a measureable 
amount of fibrin deposition. At 23 fmol TF/cm2 the amount of fibrin accumulation occluded the 
channel during most assays. Based on these data we used 2.3 fmol TF/cm2 for all experiments 
with hemophilia and healthy control samples.  
The relationship between fibrin density as measured by fluorescence intensity (FI) and D-
dimer levels was linear on surfaces of 0-23 fmol TF/cm2: D-dimer (µg/mL) = 1.3ÍFI(RFU) – 
9.7, R2 = 0.95. Therefore, we assume that the linear relationship between fluorescence intensity 
and fibrin deposition on 2.3 fmol TF/cm2 holds for normal and FVIII deficient samples. Whole 
blood from normal donors perfused over 2.3 fmol TF/cm2 at 1000 s-1 resulted in no observable 
fibrin fibers by fluorescence or D-dimer levels significantly different from perfusion over 
collagen substrates in the absence of TF (data not shown). This surface concentration of TF is 
below the threshold concentration necessary to induce fibrin formation at 1000 s-1 [28], and 
consequently experiments with hemophilia samples were only conducted at 100 s-1.  
3.4.2 Fibrin morphology in thrombi with FVIII deficiencies 
Whole blood samples from 20 HA patients (FVIII:C range 0.4–26.1%) and 9 healthy 
controls were used for this study (Table 3.1). For each sample, platelet and fibrin accumulation 
was monitored over the course of 5 min. at a wall shear rate of 100 s-1. Accumulation of fibrin 
and platelets is shown in Fig. 3.1 for a control subject and individuals with mild, moderate and 




aggregates in the first two to three minutes and then spread to the entire field of view by 5 min. 
(Fig. 3.1A, Video S1). At approximately 3 min., there was a secondary burst of fibrin 
accumulation that was observed in all control subjects (Fig. 3.2). Fibrin formation started in a 
starburst pattern, and at surface (Fig. 3.1E). Only in control subjects were fibrin networks 
observed outside of the areas adjacent to platelet aggregates. At later times (> 3 min.), fibers 
tended to align with the direction of flow. Electron microscopy revealed a network of fibers that 
was densest near platelet aggregates but that covered the entirq Mild FVIII deficiencies (5–30% 
FVIII) had similar fibrin density and accumulation rates at early times (< 3 min.) as control 
subjects (Fig. 3.2). However, there was no secondary burst of fibrin at later times (> 3 min.), just 
a steady accumulation adjacent to platelet aggregates (Video 3.S2). The fibrin in mild samples 
was most dense on and near the periphery of platelet aggregates (Fig. 3.1B). Electron 
micrographs of mild hemophilia samples show a starburst pattern of fibrin fibers emanating from 
platelet aggregates (Fig. 3.1F).  
 In severe and moderate FVIII deficiencies (1–5% FVIII), little to no fibrin was observed 
around platelet aggregates (Fig 3.1C). There was a slight increase in the accumulation rate in the 
first two minutes, after which there was no evidence of further fibrin formation (Fig 3.2, Video 
S3.3). Electron micrographs confirm that there are few, if any, large (>50 nm) fibrin fibers on or 
near platelet aggregates (Fig. 3.1G). Similar to moderate deficiencies, in severe FVIII 
deficiencies (<1%) there were little to no fibrin fibers observed (Fig 3.1D, Video 3.S4). The 
accumulation of fibrin(ogen) was modest and generally did not significantly change after the first 
three minutes of the assay (Fig. 3.2A). The overlay between the labeled platelets and the labeled 




likely platelet bound fibrinogen. There was no evidence of fibrin fibers on or near platelet 
aggregates by electron microscopy (Fig. 3.1H).  
Platelet adhesion preceded fibrin formation for all normal and patient samples. To test 
whether platelets are necessary for fibrin fiber formation we ran a set of experiments with normal 
pooled plasma (NPP) and FVIII deficient platelet poor plasma at 100 s-1. 
Table 3.1. Clinical characteristics of hemophilia A patients and controls. FVIII:C was 
measured by a one-stage clotting assay and expressed as percent of normal pooled plasma (NPP). 
Fibrin density and platelet aggregate size were measured at the end of a 5 min. flow assay on 
type I collagen and 2.3 fmol TF/cm2 at 100 s-1. Data is presented as the average and standard 
deviation of n=3.  
 
 




Platelet aggregate size 
(µm2) 
avg (stdev) 
Control 320.3 33 (11) 141 (23) 
Control 261.7 36 (3) 90 (20) 
Control 247.9 43 (5) 115 (35) 
Control 229.0 38 (5) 129 (33) 
Control 215.0 36 (7) 121 (44) 
Control 191.1 39 (10) 80 (14) 
Control 138.4 41 (6) 131 (38) 
Control 122.8 38 (8) 75 (20) 
Control 84 40 (4) 86 (21) 
Mild 26.1 36 (3) 111 (11) 
Mild 22.4 27 (2) 98 (20) 
Mild 18 27 (1) 88 (13) 
Mild 11.1 23 (4) 119 (34) 
Mild 8.3 24 (4) 165 (41) 
Moderate 4.6 15 (5) 60 (10) 
Moderate 4.3 13 (4) 66 (14) 
Moderate 3.1 12 (3) 55 (9) 
Moderate 3.1 22 (3) 40 (10) 
Moderate 2.7 12 (4) 72 (22) 
Moderate 2.4 5 (3) 50 (15) 
Moderate 2.3 6 (2) 61 (20) 
Moderate 1.9 10 (3) 81 (18) 
Severe 1.0 8 (3) 26 (6) 
Severe 0.9 9 (4) 29 (9) 
Severe 0.8 10 (2) 17 (5) 
Severe 0.5 8 (3) 15 (6) 
Severe 0.5 11 (3) 27 (8) 
Severe 0.4 11 (2) 16 (3) 
Severe 0.3 12 (3) 29 (4) 






We observed no fibrin fibers or accumulation of fluorescence signal above background in 
either case in the middle of the channel over 5 min. In NPP we did observe fibers in the corners 
of channels, which is a result of accumulation of coagulation products in the low flow areas near 
Figure 3.1 Fibrin formed under flow on collagen-TF surfaces from individuals with FVIII 
deficiencies. Recalcified whole blood was perfused over glass slides coated with 2.3 fmol TF/cm2 and 
type 1 fibrillar collagen at 100 s-1 for 5 min. Representative images of platelets (blue, anti-CD41) and 
fibrin(ogen) (green, Alexa488-fibrinogen) accumulation for a normal control (A) and hemophilia 
samples with plasma FVIII levels of 11.1% (B), 3.1% (C), and 0.4% (D) at 5 min. Scale bar = 25 µm. 
Scanning electron micrographs of thrombi from the same individuals; (E) 100% 11.1% (F), 3.1% (G), 
and 0.4% (H). Platelet aggregates are immersed in a fibrin mesh for the control (E) and form a starburst 
like pattern for mild hemophilia samples (F). The fibers on the surface in (G) and (H) are collagen 




the corners of rectangular channels. No fibers were observed anywhere in the channel with FVIII 
deficient plasma.  
3.4.3 Fibrin deposition dynamics as a function of FVIII levels 
We used three metrics to quantify the dynamics of fibrin formation; (i) the maximum 
fibrin density, (ii) the lag time to 10% of maximum fibrin formation for normal subjects (38 ± 4 
RFU), and (iii) the velocity of fibrin accumulation defined as the slope of the line defined by the 
lag time and the time to maximum fibrin density (Fig. 3.2). Both the maximum fibrin density 
(Fig. 3.2B, r = 0.80, p < 10-6) and deposition velocity (Fig. 3.2D, r = 0.85, p < 10-7) were strongly 
correlated to FVIII levels. The lag time was inversely correlated to FVIII levels (Fig. 3.2C, r = -
0.41, p = 0.04), although the dependence was not statistically significant.  
3.4.4 Clinical phenotype and platelet and fibrin accumulation 
Fibrin accumulation was supported in mild HA, but it was significantly less than for 
normal FVIII levels (Fig. 3.3A). There was not a significant difference in maximum fibrin 
density between severe and moderate HA. However, platelet aggregates were significantly larger 
in moderate HA than severe HA (Fig. 3.3B). This result suggests that the thrombin concentration 
was high enough to activate platelets in moderate HA, but not to support fibrin formation. 
 3.4.5 Thrombin generation dynamics as a function of FVIII levels 
A computational model of thrombus formation was used to estimate the effect of FVIII 
on thrombin generation. Thrombin generation was characterized by the average thrombin 
concentration (Fig. 3.4) within the thrombus and by the cumulative thrombin produced, which 







Figure 3.2. Fibrin deposition dynamics from individuals with FVIII deficiencies. (A) 
Fibrin density as a function of time for a normal control (¸) and hemophilia samples with 
plasma FVIII levels of 11.1% (r), 3.1% (£), and 0.4% (). The dynamics of fibrin 
deposition were quantified by three metrics: (B) Maximum fibrin density, which is the 
integrated fluorescence of the fibrino(gen) signal at the end of the 5 min. assay. (C) The lag 
time, which is the time to 10% of the maximum fibrin density for normal controls (4 RFU). 
(D) The velocity, which is the slope of the fibrin density curve from the lag time to the end of 
the assay. Each data point () represents a single individual with either normal or deficient 




The trends are similar for both, so we focus on the average thrombin generation here, but 
the data for cumulative thrombin production can be found in Fig. 3.S2. We used similar metrics 
to quantify the dynamics of thrombin formation as fibrin formation; (i) the maximum thrombin 
concentration, (ii) the lag time to 1 nM thrombin (concentration that activates platelets through 
PAR1 [75]), and(iii) the velocity defined as the slope of the line defined by the lag time and the 
time to maximum thrombin concentration. 
The calculated thrombin generation closely matches the trends in experimentally 
measured fibrin deposition. Platelets begin to adhere at 200-250 sec, followed by a burst in 
thrombin generation that diminishes with decreasing FVIII levels. Maximum thrombin 
concentration ranges from 50 nM at 100% FVIII to 1 nM at 1% FVIII. There was approximately 
a 5-fold decrease in both thrombin velocity and fibrin velocity between 100% and 10% FVIII. 
The velocity of both thrombin and fibrin continues to decrease between 10% and 1% FVIII, but 
at a more modest rate. Thus, the model would predict that FVIII levels from 5-10% could 
possibly present more like a mild phenotype than a moderate phenotype. However, since we only 
have one patient in that range it is difficult to draw any conclusions based on the flow assay 
experiments. 
 The lag time for fibrin and thrombin dynamics agree qualitatively; there is modest 
decrease in the lag time with increasing FVIII levels. Reduced thrombin generation for FVIII 
deficiencies can be traced to reduction in intrinsic tenase (FVIIIa:FIXa). Fig. 3.5A shows the 
spatial distribution of intrinsic tenase as a function of FVIII levels. Fig. 3.5B-D shows the total, 
platelet-derived and wall-derived FXa production. Wall derived FXa is produced solely by 
extrinsic tenase (TF:VIIa). Platelet derived FXa is produced solely by intrinsic tenase. Prior to 




in a FVIII independent manner. Following platelet adhesion (200-300 sec), FXa production 
rapidly increases through intrinsic tenase. In all cases of FVIII deficiency, extrinsic tenase is the 
major source of FXa. 
 
 
   
Figure 3.3. Fibrin density and platelet aggregate size for different clinical categories of 
hemophilia A. (A) Maximum fibrin density and (B) platelet aggregate area for severe, 
moderate and mild FVIII deficiencies compared to normal controls. Error bars represent 
standard error. Lines indicate comparisons between pairs according to Tukey’s honestly 




3.4.6 Fibrin and thrombin generation in response to rFVIII and  rFVIIa therapies  
Platelet and fibrin accumulation was measured from four individuals with severe FVIII 
deficiency on prophylactic replacement therapy before and 30 min. after injection of rFVIII. 
Representative images of final platelet and fibrin accumulation before and after treatment are 
shown in Fig. 3.6A-F. The dynamics of fibrin accumulation for patient 1 is shown in Fig. 3.6G 
and shows that treatment with rFVIII normalizes fibrin formation. In all cases there was a 
significant increase in maximum fibrin density and velocity after treatment (Fig. 3.6H, 3.6J). 
There was no difference in lag time before and after treatment (Fig. 3.6I). Patients 2 and 3 had 
post-treatment FVIII activity levels of 101% and 79%, respectively, and showed fibrin 
accumulation in the flow assays that was similar to control samples. Patients 1 and 4 had post-
treatment FVIII activity levels of 46% and 38%, respectively, and fibrin accumulation was 
slightly less than what was observed in healthy control samples (38 ± 4 RFU).  
Platelet and fibrin accumulation was measured in two individuals with severe FVIII 
deficiency with inhibitors before and 30 min. after treatment with rFVIIa. Representative images 
of final platelet and fibrin accumulation before and after treatment are shown in Fig. 3.7A-F. 
Treatment with rFVIIa changed the dynamics of fibrin formation in two ways (Fig. 3.7G). First, 
there was a dramatic decrease in lag time from 267 sec to 99 sec in patient 5 and 290 sec to 136 
sec in patient 6 (Fig. 3.7I). Second, the maximum fibrin density following rFVIIa treatment was 
39% and 42% higher than the average maximum fibrin density from healthy controls (Fig. 3.7H). 
The velocity of fibrin accumulation was within the range observed for healthy controls (Fig. 
3.7J). We simulated the effect of 0.1, 1 and 10 nM FVIIa in the plasma on thrombin generation 






In agreement with experimentally measured fibrin formation, the addition of FVIIa 
decreases lag time and increases thrombin production and average thrombin concentration. The 
thrombin lag time decreases from 290 sec at the endogenous FVIIa level (0.1 nM) to 150 sec and 
90 sec for 1 nM and 10 nM (range of anticipated plasma concentration following 90 µg/mL 
dose), respectively. The average thrombin concentration exceeds that of normal levels (100% 
Figure 3.4. Thrombin generation under flow in FVIII deficiencies. The average thrombin 
concentration within a thrombus was calculated using a spatial-temporal computational model 
of thrombus formation on 2.3 fmol TF/cm2. (A) Average thrombin concentration as a function 
of time for FVIII levels of 1, 5, 10, 20, and 100%. The dynamics of thrombin generation were 
quantified by three metrics: (B) Maximum thrombin concentration, which is the thrombin 
concentration at the end of the 5 min. simulation. (C) The lag time, which is the time to 1 nM 
thrombin. (D) The velocity, which is the slope of the average thrombin curve from the lag 
time to the end of the simulation. Each data point () represents a single simulation. The 






FVIII, 0.1 nM FVIIa) by 202% and 368% for 1 nM and 10 nM, respectively. This enhancement 
in thrombin generation is almost completely driven by extrinsic tenase. There is roughly a 2-fold 
and 4-fold increase in Xa production for 1 nM and 10 nM FVIIa, respectively. 
 
3.5 Discussion 
In this study we used microfluidic and computational models to measure thrombus 
formation on a well-defined collagen-TF surface under venous conditions in cohort of patients 
representing all three clinical phenotypes of HA (severe, moderate, mild). We also measured the 
response to replacement and bypassing therapies in individuals with severe FVIII deficiencies. 
Figure 3.5. The relative roles of intrinsic and extrinsic tenase on Xa generation. (A) The 
distribution of intrinsic tenase (FVIIIa:FIXa) within the thrombus for different FVIII levels. 
The concentration is normalized by the maximum intrinsic tenase concentration in a thrombus 
formed at 100% FVIII. The thrombus forms on 90 µm patch of TF on the bottom wall. (A) 
The total cumulative Xa production for different FVIII levels (B) and the relative contribution 
from intrinsic tenase (C) and extrinsic (TF:FVIIa) tenase (D). Xa production is normalized by 






 This combined experimental and computational approach yields new insights into the 
biophysical mechanisms that regulate thrombus formation in HA. In comparison to static 
conditions, flow can either limit or enhance local enzyme concentrations and fibrin 
polymerization reactants [27, 31, 76]. In the case of FVIII deficiencies, flow dilutes thrombin 
such that reduction in thrombin generation is more severe than under static conditions.  
Figure 3.6. Fibrin deposition dynamics in response to rFVIII treatment. Four patients (1-
4) with severe hemophilia where treated with rFVIII (see Methods for doses). Recalcified 
whole blood was perfused over glass slides coated with 2.3 fmol TF/cm2 and type 1 fibrillar 
collagen at 100 s-1 for 5 min before and 30 min after treatment with rFVIII. Platelets (blue, 
anti-CD41), fibrin(ogen) (green, Alexa488-fibrinogen) and their overlay immediately before 
(A-C) and 30 min. after (D-F) rFVIII injection. (G) Transient fibrin density pre-treatment () 
and post-treatment () in comparison to a normal control (¸). The dynamics of fibrin 
deposition before (black bars) and after (white bars) was characterized by (H) maximum 
fibrin density, (I) the lag time, and  (J) the velocity. Error bars represent standard deviations of 




For example, there is a 62% reduction of peak thrombin concentration between 100% and 
1% FVIII levels under static conditions [77] compared to a 98% reduction under flow observed 
in this study. Similarly, a 69% reduction in the rate of fibrinopeptide A release in severe HA 
compared to normal controls was reported in a static whole blood coagulation assay [78], 
compared to an average 94% reduction in fibrin deposition velocity under flow. On the other 
hand, convective transport by flow increases the flux of rFVIIa to the TF-rich surface, and thus 
decreases the lag time to thrombin generation and fibrin formation much faster than by diffusion 
alone. 
Fibrin formation was supported by mild FVIII deficiencies, but not moderate or severe 
deficiencies. This is a novel observation that supports clinical evidence that individuals with mild 
FVIII deficiency (5-40%) do not experience bleeding except after severe trauma or surgery and 
that venous thrombosis is rare in these individuals [79]. Computations predict a local thrombin 
concentration of 5-20 nM over FVII levels of 5-40%. Based on previous studies, this thrombin 
concentration can support fibrin formation under flow, but only at wall shear rates of 10-25 s-
1[13]. Under static conditions, fibrin formation is supported at thrombin concentration of less 
than 1 nM. The shear rate may be lower in and near the nascent thrombus due to perturbations in 
the flow field by platelets that protect coagulation products from dilution by flow.  
This reasoning is supported by the observation that platelet adhesion preceded fibrin 
formation under all conditions. Even a very high surface TF concentration (23 fmol TF/cm2) 
could not support fibrin formation in the absence of platelets at 100 s-1. Thrombus formation on 
homogenized atherosclerotic plaques containing both collagen and TF demonstrate similar 
trends; platelet accumulation precedes fibrin formation and no fibrin is observed in the absence 






Platelet aggregate size was larger in moderate FVIII deficiencies compared to severe 
deficiencies. This observation suggests that while the local thrombin concentration in moderate 
deficiencies was unable to support fibrin deposition, it was high enough to activate platelets.  
 
Figure 3.7. Fibrin deposition dynamics in response to rFVIIa treatment. Two patients (5-
6) with severe FVIII deficiency with high inhibitor titer were treated with 90 µg/mL rFVIIa. 
Recalcified whole blood was perfused over glass slides coated with 2.3 fmol TF/cm2 and type 
1 fibrillar collagen at 100 s-1 for 5 min before and 30 min after treatment with rFVIIa. 
Platelets (blue, anti-CD41), fibrin(ogen) (green, Alexa488-fibrinogen) and their overlay 
immediately before (A-C) and 30 min. after (D-F) rFVIIa injection. (G) Transient fibrin 
density pre-treatment () and post-treatment () in comparison to a normal control (¸).The 
dynamics of fibrin deposition before (black bars) and after (white bars) was characterized by 
(H) maximum fibrin density, (I) the lag time, and  (J) the velocity. Error bars represent 
standard deviations of n=3. Lines indicate comparisons between pairs according to the Mann-






Treatment of FVIII deficiency with replacement therapy normalized fibrin deposition, 
while treatment with bypass therapy significantly altered fibrin deposition dynamics compared to 
healthy controls. For patients receiving replacement therapy (rFVIII), the post-treatment FVIII 
activity was equal to or less than normal FVIII activity. Therefore, the observation that fibrin 
deposition was equal to or slightly less than the normal control is expected. For the two patients 
receiving bypass therapy (rFVIIa), a decreased lag time and increased cumulative fibrin 
deposition were observed. The computational model predicts faster assembly of the TF:FVIIa 
Figure 3.8. Thrombin generation under flow for rFVIIa treatment. The computationally 
calculated cumulative thrombin production (A), average thrombin concentration (B), 
maximum thrombin concentration (C), velocity of thrombin production (D) and lag time (E) 
for 1% FVIII levels at 0.1, 1, and 10 nM FVIIa plasma concentration compared to 100% 
FVIII levels and 0.1 nM FVIIa. The cumulative thrombin production is normalized by the 




complex owing to a higher flux of FVIIa being delivered to the surface compared to endogenous 
FVIIa levels. In the absence of TF, previous studies have shown that adding 13 nM rFVIIa 
enhances the final accumulation of platelets on collagen at 1600 s-1, but does not affect the lag 
time [51]. The increase in platelet accumulation is thought to be a function of rFVIIa binding to 
platelets followed by subsequent activation of FX [81]. In our computational model, we did not 
account for rFVIIa binding to platelets and still found that 1-10 nM of FVIIa could boost 
thrombin generation significantly through extrinsic Xase. The contribution of platelet bound 
rFVIIa on fibrin formation under flow requires further study. Nevertheless, our experimental and 
computational results suggest that treatment of FVIII deficiency with rFVIIa could lead to 
prothrombotic risks in agreement with clinical observations [82]. 
There is growing appreciation for the utility of computational models in modeling 
coagulation and platelet function, in that they can integrate the details of complex phenomena to 
yield mechanistic insight or to test novel hypotheses [83-86]. Perhaps in the future these 
computational models will allow scientists and clinicians to be able to predict the degree of 
hemostatic responses in patients with clotting factor deficiencies. In this study we used a 
computational model of thrombus formation that incorporates platelet adhesion, aggregation and 
coagulation to predict the effect of perturbations to coagulation (FVIII deficiency and rFVIIa 
treatment) on thrombin generation. There was agreement between the computationally predicted 
thrombin and experimentally measured fibrin dynamics in terms of lag time, maximum 
concentration, and rate of production.  
The lag time was associated with the time for substantial platelet adhesion (>3-4 min) and 
was relatively insensitive to FVIII levels in comparison to FVIIa levels, which dramatically 




fold between 100% and 10% FVIII levels. The fibrin density was less sensitive to FVIII levels 
below 10% than the thrombin concentration due to the background fluorescence caused by 
labeled fibrinogen. However, there was a decrease in platelet aggregate size between 1% and 
10% levels that corresponds with the predicted drop in local thrombin concentrations that 
approach subthreshold concentrations of thrombin (~1 nM) for activating PAR1 [75]. While the 
mechanisms that regulate thrombin generation and fibrin formation are different, observations 
from in vivo and in vitro assays using a platelet bound thrombin sensor show that thrombin and 
fibrin co-localize in the interior of a clot [41]. This suggests that fibrin is a good proxy for 
thrombin concentration in flow-based assays.   
In summary, FVIII deficiencies can profoundly influence thrombin and fibrin formation 
on TF-rich substrates at venous shear rates. The primary effect of FVIII deficiency is that the rate 
of thrombin generation becomes slower on the platelet surface and thus the characteristic burst of 
thrombin is absent. Under flow, the situation is further exacerbated because the local thrombin 
concentration is diluted more quickly than by diffusion alone. In the case of mild FVIII 
deficiencies and in the presence of high surface TF concentrations, the local thrombin 
concentration is sufficient to promote fibrin formation in and adjacent to platelet aggregates. 
Platelets play a central role in both providing a burst in thrombin production and in providing a 
physical shelter for coagulation reaction and fibrin formation. Treatment of severe FVIII 
deficiency with rFVIIa gives thrombi that form faster and accumulate more fibrin than healthy 
controls.  
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4.1 Abstract 
Blood flow regulates coagulation and fibrin assembly by controlling the rate of transport 
of zymogens, enzymes and plasma proteins to and from the site of an injury. The objective of 
this work was to define the hemodynamic conditions under which fibrin can form under flow on 
tissue factor (TF)-rich substrates. TF-coated silica beads (~800 nm) were patterned into 18-85 
µm spots. Normal pooled plasma and factors VIII, IX, and XI deficient plasmas were perfused 
over the beads coated with 0.08, 0.8, and 8 molecules-TF/µm2 at shear rates of 50–1000 s-1. 
Fibrin deposition and thrombin generation were measured by fluorescence microscopy in a 
hydrodynamic focusing microfluidic device. Fibrin deposition was supported on patterned bead 
spots, but not planar TF substrates at the same surface TF concentration.  
There was a threshold spot size and a shear rate dependent TF concentration that was 
necessary to support fibrin polymerization. FVIII and FIX had minor effects on fibrin dynamics 
at 8 molecules-TF/µm2, but were essential at 0.8 molecules-TF/µm2. The absence of FXI 
influenced thrombin generation and fibrin deposition at both 0.8 and 8 molecules-TF/µm2. These 
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results show that fibrin deposition requires perturbations in the flow field that protect reactions 
from dilution by flow under venous and arterial conditions. FVIII and FIX have a modest effect 
on fibrin deposition at high TF concentrations, but are necessary for fibrin deposition at low TF 
concentrations. FXI amplifies thrombin generation under flow at both low and high TF 
concentrations.  
4.2 Introduction 
The dynamics of fibrin polymerization and thrombin generation have been extensively 
characterized under static, or no flow, conditions in closed systems where biochemical reactions 
can proceed to completion. These approaches have been critical for measuring the myriad of 
factors that influence thrombin generation, fibrin polymerization and fibrinolysis [87, 88]. 
However, in vivo these phenomena are further constrained by dilution by blood flow. In this 
study, we examine how shear rate and surface TF concentration influence fibrin assembly and 
thrombin generation in a cell-free, plasma system. 
 Flow can either promote or inhibit coagulation depending on the relative rates of 
biochemical reactions to transport (diffusion and convection) to and from a procoagulant surface. 
Cases where transport is slow compared to reaction are transport limited. The generation of 
factor Xa (FXa) on TF:FVIIa is transport limited. That is, as the shear rate increases, the rate of 
FXa generation increases, at least over the shear rate range of 57–1130 s-1 [26]. Conversely, 
cases where transport is fast compared to reaction are reaction limited. Thrombin generation is 
reaction limited. The rate of thrombin generation is constant over shear rates of 100–1000 s-1 
[27]. As the shear rate increases, the local thrombin concentration is diluted by flow. Fibrin 
polymerization can be either transport limited or reaction limited depending on thrombin 




 Fibrin deposition typically follows blood cell adhesion. For example, flow assays on 
homogenized atherosclerotic plaques show that fibrin forms after the formation of platelet 
aggregates [80]. This is likely due to the procoagulant surface of activated platelets, but also to 
small perturbations in the flow field around platelet aggregates. Computational models of platelet 
aggregation predict that these perturbations create low flow regions that protect agonists from 
dilution [84]. These observations suggest that coagulation and fibrin polymerization may need 
physical protection from flow in order to support the formation of fibrin fibers.  
  In this study, we decouple blood cell adhesion and aggregation from the mechanisms 
that regulate coagulation and fibrin polymerization under flow. We describe a method for 
synthesizing and patterning TF-coated silica beads. By flowing plasma over these beads we 
identified conditions where fibrin polymerization was transport or reaction limited. Experiments 
with factors VIII, IX and XI deficient plasmas demonstrated differences and similarities in how 
these deficiencies affect thrombin generation and fibrin polymerization under static and flow 
conditions. 
4.3 Materials and Methods 
4.3.1 Reagents 
L–α-phosphatidylcholine (PC) and  L–α-phosphatidylserine (PS) were from Avanti 
Polar Lipids (Alabaster, AL, USA). Texas red 1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine (DHPE) and Alexa Fluor 488 protein labeling kit were from Invitrogen 
(Carlsbad, CA, USA). Boc-Val-Pro-Arg-AMC was from Peptide Institute Inc. (Osaka, Japan). 
3,3'-Pacific Blue anti-human CD41 was from BioLegend (San Diego, CA). Non-lipidated 
recombinant human tissue factor (TF), tissue factor ELISA and D-Dimer ELISA were from 




Bend, IN). Normal pooled plasma (NPP) and factors II, VIII, IX, X and XI deficient plasmas in 
3.8% sodium citrate were from George King Biomedical (Overland Park, KS). HEPES buffered 
saline (HBS; 20 mM HEPES, 150 mM NaCl, pH 7.4) was made in house. (3-
aminopropyl)trimethoxysilane  (APTMS), tetraethyl orthosilicate (TEOS) and all other 
chemicals were from Sigma Aldrich  (St. Louis, MO).   
4.3.2 Preparation of TF coated silica beads  
Recombinant human TF was incorporated into liposomes according to previously 
developed protocols [72]. Silica beads were synthesized using the Stober process [89]. TEOS 
was added drop wise to a solution of water, ethanol and ammonium hydroxide and stirred for 2 
h. The resulting suspension was centrifuged at 2000 rpm for 5 min, washed in ethanol then 
deionized water, and finally resuspended at a concentration of 5 mg/ml in 4% hydrogen peroxide 
and 0.4 M HCl to enhance their hydrophilicity. The suspension was heated to 80 - 90°C for 10 
min, cooled to 20 °C, centrifuged at 2000 rpm for 5 min, washed three times with deionized 
water and finally resuspended in HBS and stored at room temperature. 
 Prior to an experiment, silica beads are centrifuged and resuspended in deionized water, 
then centrifuged and resuspended to 0.16 g/ml and combined with TF liposomes (2.4 mM) in 
HBS with or without 4.8 mM CaCl2. The fidelity of the bilayer was determined by observing 
their stability in solution for 1 week and the formation of a bilayer was confirmed by incubation 
in heptane. To change the surface TF concentration, liposomes containing TF were diluted with 
liposomes (PC:PS:DHPE 80:19.5:0.5) without TF, while maintaining the same total lipid 
concentration (2.4 mM). The size and zeta potential of the beads were measured using a 




The TF activity of the beads was measured using previously developed protocols [90]. 
Briefly, 100 µL of TF beads were added into well in a 96-well microplate and allowed to settle 
for 1 h. Next, 100 µL of NPP was added to each well with 10 mM CaCl2 and 10 µM boc-VPR-
AMC. Fluorescence was read in a plate reader (Victor X, PerkinElmer). Fractional conversion of 
the substrate was calculated by: C=(F – Fmin)/(Fmax – Fmin), where C is the fractional conversion, 
F is the instantaneous fluorescence, Fmin is the minimum fluorescence, and Fmax is the maximum 
fluorescence in that well during the experiment. The initiation time was defined as the time when 
C is ≥0.05.  
4.3.2 Patterning TF-coated silica beads and TF lipid bilayers 
Microblots were defined by soft lithography in PDMS and consisted of arrays of holes 
with diameters of 20, 50 and 100 µm and 200 µm center-to-center spacing (Fig. 4.S1). Glass 
slides were treated with 40 wt% APTMS in anhydrous ethanol solution for 45 min. TF-coated 
silica beads were incubated for 4 h on APTMS functionalized slides and rinsed to remove excess 
beads. Substrates were kept hydrated to maintain the fidelity of the lipid bilayers. PDMS 
microblots were brought into contact for 1 min with the bead-coated slide immersed in HBS 
using a custom press and then removed. The surface coverage of beads on a spot was calculated 
by thresholding the fluorescent images using Otsu’s method in ImageJ (NIH, Bethesda, MD). 
The number of beads per spot was calculated by dividing the total area of the beads by the 
projected area of a single bead. Lipid bilayers were microcontact printed onto glass slides using 




4.3.3 Blood collection and treatment 
Five milliliters of whole blood were collected into a syringe containing trisodium citrate 
(129 mM, 1:10) by venipuncture in accordance with the Declaration of Helsinki and under the 
University of Colorado, Boulder Institutional Review Board approval. Donors had not consumed 
alcohol for 48 h before, nor taken any prescription or over-the-counter drugs during the 10 days 
prior. Blood was incubated for 10 min with anti-human CD41 at 1:100 at 37 °C and recalcified 
(7.5 mM CaCl2, 3.75 MgCl2) immediately prior to the assay.  
4.3.4 Plasma and whole blood flow assays  
A PDMS microfluidic hydrodynamic focusing device (W=1000 µm, H=100 µm) was 
vacuum-sealed to glass slides. HBS was infused through the two side channels to provide the 
focusing of plasma, which was perfused through the middle channel (Fig. 4.1). The flow rate was 
set to the desired wall shear rate by: γ=6 Q/ H2 W where γ is the shear rate, Q is the volumetric 
flow rate, W is the width and H is the height. Citrated NPP and FII, FX, FVIII, FIX and FXI 
deficient plasmas were defrosted at 37 °C immediately before flow experiments. Exogenous 
Alexa 488-labeled fibrinogen (100:1 plasma fibrinogen:labeled fibrinogen) and boc-VPR-AMC 
(100 µM) were added to the plasma. The citrated plasma or whole blood was re-calcified to 7.5 
mM CaCl2 and perfused through the channel at shear rates of 50, 100, 250, 500 and 1000 s-1 
4.3.5 Data acquisition and image analysis 
Fibrin and platelet deposition and thrombin generation were measured for 10 min. Images 
were recorded by epifluorescence microscopy (40X, NA=0.6, IX81, Olympus). A motorized 
stage visited spots at x=0, 400, 800 and 1200 µm along the center row of beads, where x=0 




substrate was calculated on a 100 µm region-of-interest centered over the spot. A standard curve 
of integrated fluorescence intensity of a 100 µm spot as a function of fibrinogen concentration 
was generated in a 15 µm microfluidic channel (height of highest fibrin gel from flow 
experiments): Fluorescnce [RFU]=29,000 Fibrinogen [mg/ml]+5700. After the assay, a heparin 
wash buffer (HBS, 7.5 mM CaCl2, 1 U/mL heparin) was used to rinse the channel for 5 min at 50 
s-1, followed by 2.5% glutaraldehyde for 5 min at 50 s-1.  
The microfluidic device was removed and then samples were coverslipped for confocal 
microscopy or prepared for electron microscopy. Six metrics were used to quantify dynamics in 
the assay; (i) fibrin lag time – defined as the first observable fibrin fiber in the image sequence, 
(ii) thrombin lag time – defined as the time to 5% of the maximum fluorescence intensity of NPP 
perfused at 50 s-1 over 8 molecules-TF/µm2, (iii) the maximum fibrin and (iv) maximum 
thrombin – defined as the integrated fluorescence of a 100 µm region-of-interest centered on the 
bead in the last frame, (v) fibrin deposition rate and (vi) thrombin generation rate – defined as the 
slope between the respective lag times and 95% of the maximum. To measure the fibrin fiber 
angular distribution, the line tool in ImageJ was used to trace each fiber and the angle from the 
axis of flow was measured (0-180°) in confocal images. For each condition 50-100 fibers were 
measured at 1 µm intervals through the thickness of each condition (n=3).  
4.3.6 D-dimer measurements 
Plasmin (0.48 mg/ml) was perfused through the device at a flow rate of 5 µL/min for 10 
min, and then flow was stopped for 30 min to allow for fibrin digestion. The digested fibrin 
samples were collected and snap frozen at -70° C until assayed by ELISA. Since fibrinogen and 





4.3.7 Scanning electron microscopy  
Samples were prepared for scanning electron microscopy (SEM) as previously described 
[31]. Images were taken with JOEL 7000 (Hitachi, Tokyo, Japan). The diameters of fibrin fibers 
and were measured in ImageJ.  
4.3.8 Statistical Analysis 
For comparing results over the five shear rates for a given TF concentration one way 
ANOVA was used to determine differences between groups, followed by a post hoc Bonferroni 
test. For comparing results between factor deficient plasma to NPP a Student’s t-test was used to 
determine differences. Normality was confirmed with the Jarque-Bera test. All calculations were 
performed using Matlab (Natick, MA, USA). Data is presented as the average ± standard 
deviation of n=3-5. Significant differences (p<0.01) are represented by an asterisk (*). 
4.4 Results 
4.4.1 Characterization of TF-coated silica beads 
TF was incorporated into lipid vesicles at a lipid:TF ratio of 8700:1. The area of each 
lipid head group is ~0.71 nm2 [92], which gives 80 molecules-TF/µm2 assuming half of the TF 
molecules are oriented extracellular domain facing outwa rd. TF containing vesicles rupture and 
form stable lipid bilayers on silica beads in the presence of CaCl2. In the absence of calcium, the 
lipids desorb from the surface over several hours. Silica-TF beads do not aggregate when stored 
at room temperature and maintain their activity for up to a week. The lipid-coated beads had a 
zeta potential of -48 mV and a size of 797±17 nm at pH 7.4.  
To confirm a bilayer, the beads were incubated with heptane for two weeks and there was 




thrombin generation (Appendix C, Figure C4). Surface concentration of 0.08, 0.8 and 8 
molecules-TF/µm2 gave initiation times of 202±26, 101±17, and 29±5 seconds. Initiation time on 
lipid coated beads without TF and uncoated silica beads was 38 min. and 35 min., respectively, 
suggesting that thrombin generation via the intrinsic pathway was negligible over the time scale 
of the flow experiments. 
4.4.2 Fibrin fibers preferentially deposit on TF-beads compared to planar TF bilayers 
We patterned two TF-rich surfaces; planar lipid bilayers defined by microcontact printing 
and TF-coated silica beads defined by microblotting. The lipid bilayer spots had a diameter of 
86±6 µm (n=110). The bead spots had a diameter of 85±4 µm (n=110). Spots contained 
5170±630 beads that covered 43%±5% of the spot. The center-to-center spacing of spots in both 
cases was 200 µm. A microfluidic device with hydrodynamic focusing was used to perfuse 
plasma through the center of the channel over the patterned surfaces and prevent coagulation 
products from accumulating in channel corners (Fig. 4.1B).  
 On spots with a bead surface concentration of 8 molecules-TF/µm2, we observed the 
formation of a fibrin gel and burst in thrombin generation at 50 s-1 (Fig. 4.1C-D, Movie S1). This 
bead surface concentration corresponds to a spot surface concentration of 14.7 molecules-
TF/µm2 (bead surface concentration×bead surface area/spot surface area). On a planar 
microcontact printed spot with a surface concentration of 14.7 molecules-TF/µm2, we observed 
no fibrin fibers at shear rates as low as 20 s-1 on surfaces blocked with either BSA or fibrinogen. 
In fact, no fibrin fibers were observed on planar surfaces up to 40 molecules-TF/µm2. Decreasing 
the bead size to 300 nm still supported fibrin deposition, although at a diminished level 






4.4.3 A threshold spot size is necessary to support fibrin formation under flow 
TF-coated silica beads (8 molecules-TF/µm2) were patterned using 20, 50 and 100 µm 
microblots. The 20 and 50 µm holes resulted in bead spot diameters of 18±4 µm and 44±4 µm 
with 250±40 and 1300±140 beads/spot, respectively (n=110). Fibrin fibers formed on the larger 
two spots, but not on the smallest spots following at 50 s-1 (Fig. 4.2). Fibrin fibers were first 
Figure 4.1. Thrombin generation and fibrin deposition on patterned TF-coated silica 
particles under flow. A. Array of bead spots patterned by microblotting as described in the. 
Each spot contains 5170 ± 630 silica beads (d = 797 ± 17 nm) that are coated with a lipid 
bilayer (PC:PS:DHPE 80:19.5:0.5) containing TF. DHPE is labeled with Texas Red for 
purposed of visualization. B. A microfluidic hydrodynamic focusing device was used to keep 
plasma (green) away from the walls via two sheaths of buffer (yellow). C. Time series of 
fibrin deposition on a single patterned bead spot with a diameter of 86 µm at a shear rate of 50 
s-1 and a surface concentration of 8 molecules-TF/µm2 on the beads. Alexa 488-labeled 
fibrinogen was added to the plasma at a molar ratio of 1:100 (labeled:unlabeled) to visualize 
fibrin formation. D. Time series of thrombin generation as measured by cleavage of the 




observed in the middle of a spot and towards the downstream edge, and then filled in the 
upstream edge over time. No fibrin was observed on plain silica beads or lipid-coated silica 
beads without TF, even for 30 min assays, suggesting that thrombin generation via the intrinsic 
pathway alone does not support fibrin deposition. In whole blood assays fibrin localized on 50 






For 8 molecules-TF/µm2, fibrin was supported at all wall shear rates. For 0.8 molecules-
TF/µm2, fibrin formation was observed at wall shear rates less than or equal to 250 s-1. For 0.08 
molecules-TF/µm2, fibrin formation was observed only at wall shear rates of less than or equal to 
100 s-1. There was a sharp transition from a transport limited to a reaction limited regime at 0.8 
Figure 4.2. Fibrin formation as a function of spot size. NPP was perfused over bead spots 
with diameters of 85±6 µm (A), 44±4 µm (B) and 18±4 µm (C) at a wall shear rate of 50 s-1 
and 8 molecules-TF/µm2 on the beads. Fibrin formation was supported on the two larger spots 




and 8 molecules-TF/µm2. At both concentrations, at 50–100 s-1 there was a burst of thrombin 
followed by a rapid increase in fibrin deposition (Fig. 4.3). In these cases, fibrin deposition is 
transport limited because the fibrin and thrombin lag time were independent of shear rate (Fig. 
4.4). At the higher shear rates, we observed a transition into a reaction limited regime, where lag 





Figure 4.3. Fibrin deposition and thrombin generation as a function of shear rate and 
TF concentration. NPP was perfused over spots with bead surface concentrations of 0.08, 
0.8, and 8 molecules-TF/µm2 at 50, 100, 250, 500 and 100 s-1. The data was normalized by 
the maximum integrated fluorescence intensity at the lowest shear rate (50 s-1) and highest TF 
concentration (8 molecules-TF/µm2) and presented in relative fluorescence units (RFU). Each 






4.4.5 The influence of shear rate on fibrin morphology 
Fibrin gel height penetrated further into the lumen with decreasing shear rate (Fig. 4.5A). 
Gels formed at 50 s-1 had a height of 15.3±2.4µm, while those formed at 1000 s-1 had a height of 
1.1±0.9 µm. The concentration of fibrin(ogen) in the gels formed at 50 and 100 s-1 was 
Figure 4.4. Metrics of dynamic fibrin deposition and thrombin as a function of shear 
rate and TF concentration. Metrics of dynamic fibrin deposition and thrombin generation 
(lag time, rate, maximum) as a function of shear rate and TF concentration. The dotted line on 
the lag time graphs (left column) represents 600 s. Bars that reach the dotted line indicate that 
either no fibrin fibers were observed or there was no increase in the thrombin substrate signal 
over the background over the duration of the assay. Differences within a group for a given TF 
concentration were determined by ANOVA and Bonferroni post hoc test to compare pairs. 




approximately five-fold the plasma concentration of fibrinogen (Fig. 4.S7), which is consistent 
with SEM images that show higher density of fibrin fibers at lower shear rates (Fig. 4.5E).   
 Fibrin fibers aligned in the direction of flow in a shear rate dependent manner (Fig. 4.5B, 
4.D). At 50 and 100 s-1, the fibers were isotropically oriented in a starburst pattern. From 250 to 
1000 s-1 the fibers become more orientated with the direction of flow. Fibrin fiber diameter 
decreased with increasing wall shear rate (Fig. 4.5C, E).  
4.4.6 The effect of FVIII, FIX, and FXI deficiencies on fibrin deposition  
NPP and FII, FVIII, FIX, FX and FXI deficient plasma were perfused at 50 s-1 over spots 
of 0.8 and 8 molecules-TF/µm2 beads (Fig. 4.6A). No fibrin was formed with FII and FX 
deficient plasmas. At 8 molecules/µm2, fibrin and thrombin lag times for FXI deficient plasma 
were prolonged compared to NPP (Fig. 4.6C). The difference between NPP and the factor 
deficient plasmas was more evident in thrombin generation (Fig. 4.6A).  
FVIII deficient plasma was indistinguishable from NPP, but resulted in smaller fibers 
(Fig. 4.6B). FIX had a prolonged thrombin lag time, and larger fiber diameters than NPP. FXI 
deficient plasma had both a longer thrombin lag time and slower thrombin generation than NPP, 
as well as larger fibers. At 0.8 molecules-TF/µm2, there was almost a complete absence of fibrin 
for FVIII and FIX deficient plasma, while fibrin deposition was observed for the FXI-deficient 
plasma, but at a lower density than NPP (Fig. 6C). The trends for thrombin generation were 
similar to fibrin deposition. 
4.5 Discussion 
In this study, we describe a  plasma-based flow assay for measuring fibrin deposition and 




simulate the presentation of adherent TF-bearing cells or microparticles. We found that fibrin 
polymerization required protection from dilution by flow over a physiologic range of shear rates.  
Experiments with FVIII, FIX and FXI deficient plasmas showed that coagulation under flow has 
similarities and differences with static conditions. In experiments on planar lipid bilayers we 




Figure 4.5. The effect of shear rate on fibrin morphology. NPP was perfused over a bead 
surface concentration of 8 molecules-TF/µm2 at 50 s-1 for 10 min. A. Fibrin gel height was 
measured by confocal microscopy. B. Orientation of fibrin fibers with the direction of flow. 
The peaks in the fiber orientation distribution for 500 and 1000 s-1 at 0° indicate alignment 
with flow. C. Fibrin fiber diameter (n=100). Epifluorescence (D) and SEM (E) images of 
fibrin deposition on bead spots. Differences within a group were determined by ANOVA and 
Bonferroni post hoc test to compare pairs. Significant differences (p < 0.01) are represented 






Figure 4.6. The effect of FVIII, FIX and FXI on fibrin depositions and thrombin 
generation. A. Normal pooled plasma (NPP) and FVIII, FIX and FIX deficient plasmas were 
perfused on 85 µm bead spots at 50 s-1 and surface concentrations of 0.8 and 8 molecules-
TF/µm2. The data were normalized by the maximum integrated fluorescence intensity for 
NPP at the lowest shear rate (50 s-1) and highest TF concentration (8 molecules-TF/µm2) and 
presented in relative fluorescence units (RFU). B. Fibrin fiber diameters at 50 s-1 and 8 
molecules-TF/µm2 presented as their average and standard deviation (n = 100). C. Metrics of 
dynamic fibrin deposition and thrombin generation (lag time, rate, maximum) as a function of 
shear rate and TF concentration. The dotted line on the lag time graphs (left column) 
represents 600 sec. Bars that reach the dotted line indicated that either no fibrin fibers were 
observed or there was no increase in the thrombin substrate signal over the background over 
the duration of the assay. Each data point represents the average and standard deviation of 
three replicates. Differences between NPP and factor deficient plasmas were determined by a 
Student’s t-test. Significant differences (p < 0.01) are represented by an asterisk (*) and bars 




This is in agreement with results in a fibrinogen-thrombin system where no fibrin was 
observed on a planar surface at 100 s-1 even at near-wall thrombin concentration of ~1 µM [31]. 
By replacing a planar substrate with TF-coated beads, fibrin deposition was supported. It is 
possible that TF activity is different in these two immobilization schemes, but we consider this 
unlikely as the surface of the glass slide and the beads are chemically identical (silica).  
The degree of fibrin deposition correlated to bead size; 300 nm beads had reduced fibrin 
deposition compared to 800 nm beads. These data suggest that the beads protect coagulation 
reactions and fibrin polymerization from dilution by flow. The existence of micrometer scale 
objects may better mimic a vascular injury than a flat surface since platelet and leukocyte 
adhesion precedes fibrin formation [80, 93]. Fibrin can form in the absence of blood cell 
adhesion, for example, on activated endothelial cells [94]. However, the surface of the 
endothelium has micrometer scale undulations that may protect coagulation reaction from 
dilution [95].  
 A threshold spot size of was necessary to support fibrin formation for both flowing 
plasma and whole blood. A threshold spot size has also been reported studies of thrombin 
generation on TF lipid bilayers, although at lower shear rates [30]. It seems that the 
hydrodynamic constraints on fibrin deposition are more stringent than thrombin generation since 
some perturbation of the flow was necessary. Nevertheless, in both systems increasing the spot 
size results in a downstream accumulation of coagulation products that eventually supports a 
thrombin burst. 
 Both transport and reaction limited regimes were observed in fibrin deposition and 
thrombin generation. The transport limited regime is characterized by lag times that are 




assays [77]. Following lag time, there is a rapid deposition of fibrin followed by slower 
deposition at long times (>400 s), which may be indicative of the fibrin gel blocking access of 
zymogens to the TF-rich surface, at least at lower shear rates [96]. In the reaction limited regime, 
fibrin fibers were limited to the interstitial space between beads or in some cases no fibrin fibers 
were produced at all. In the former case, fibrin fibers slowly accumulated on the spots, but there 
was no evidence of a thrombin burst.  
 In whole blood the critical TF concentration needed to induce coagulation on 175 µm 
collagen-TF spots is 3.6, 8.4, and 10.2 molecules-TF/µm2 at 100, 500 and 1000 s-1, respectively 
[28]. Here, we found that 8 molecules-TF/µm2 could support fibrin gel formation from 50–500 s-
1. Thus, the TF-coated silica beads are a reasonable proxy for platelets with respect to their 
ability to support coagulation. Whole blood experiments on collagen-TF also show that fibrin 
deposition is limited to ~20 µm from the surface [60], which is in close agreement with ~15 µm 
fibrin gels on TF-coated beads.  
 In agreement with studies on TF-bearing cells and platelets [97, 98], we found that 
increasing shear rate, and thus shear stress, led to an increase in the orientation of fibers with the 
direction of flow. The shear stress needed to align fiber fibers seems to vary with the 
experimental system from as low as 20 s-1 on activated platelets to >500 s-1 on TF-coated beads 
[98].  
 The relative role of the intrinsic and extrinsic tenase on fibrin formation depended on TF 
concentration. At 8 molecules-TF/µm2, there was little difference in the total fibrin deposited 
from plasma deficient in FVIII and FIX. At 0.8 molecules-TF/µm2, fibrin deposition and 
thrombin generation was dramatically reduced. These results agree with static assays where 




[18]. These results are in accordance with the clinical presentation of FVIII and FIX deficiencies, 
where bleeding is typically observed in vascular beds thought to have low TF content (e.g., 
muscles, joints).  
 The role of FXI as an amplifier of thrombin generation was observed at both high and 
low TF concentrations. This is in contrast with static assays where FXI plays a role only at low 
TF concentrations [77, 99]. At 8 molecules-TF/µm2, FXI-deficient plasma had prolonged lag 
times compared to NPP, supporting a role for FXI as a positive feedback mechanism in 
propagating thrombin generation away from a TF-rich surface [100]. The fibrin fibers formed 
from FXI-deficient plasma were also thicker than those from NPP, which is indicative of a lower 
local thrombin concentration [101]. Thicker fibers lyse faster [102], and individuals with FXI 
deficiencies tend to bleed in areas of high fibrinolytic activity. At 0.8 molecules-TF/µm2, FXI-
deficient plasma showed reduced thrombin generation and fibrin deposition compared to NPP, 
but not as severe of a reduction as FVIII and FIX deficiencies. This result concurs with the mild 
clinical bleeding observed in severe FXI deficiencies, compared to the major bleeding in severe 
FVIII and FIX deficiencies.  
 We have developed a plasma-based flow assay for measuring thrombin generation and 
fibrin deposition. This method has some advantages over whole blood assays, including 
eliminating the variability in platelet function [73] and allowing for the use of frozen plasmas as 
opposed to freshly drawn blood. Here, we have defined how shear rate, TF concentration, and 
FVIII, FIX and FXI influence thrombin generation and fibrin deposition in the assay. We expect 
this method can be used to determine how other molecules in the coagulation, anticoagulation 
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THE ROLE OF FXI DEFICIENCY ON CLOT PROPAGATION 
5.1 Abstract  
Recent studies conducted in Israel have shown that individuals with deficiencies in a 
coagulation protein, called factor XI (FXI) are protected against stroke and deep vein 
thrombosis, but not myocardial infarction (104,105). The mechanism for this protection is still 
unknown. One potential explanation, which has not been studied, is the role of blood flow on 
FXI-dependent clot growth and stability. In this study we examined fibrin formation and 
thrombin generation on TF rich surfaces in the absence of FXI over a range of physiological flow 
conditions. NPP and FXI deficient plasma were perfused over 100 µm spots of TF coated silica 
beads at 0.8 molecules-TF/µm2 and 0.08 molecules-TF/µm2 at shear rates of 25, 100, 250 and 
500 s -1 for 10 min to monitor fibrin deposition and thrombin generation.  
Clot lysis was triggered using tissue plasminogen activator (tPA), and thrombomodulin 
was used to decrease the procoagulant activity and to discriminate the role of FXI in clot 
formation in the microfluidic assay.  At 0.8 molecules-TF/µm2, fibrin deposition and thrombin 
generation decreases with an increase in shear rate both NPP and FXI-deficient plasma. There 
was a sharp transition from the transport limited regime at 25 and 100 s-1 to the reaction limited 
regime at 250 s-1 based on lag times There were little or no differences between NPP and FXI-
deficient plasma based on fluorescence intensity. At 0.08 molecules-TF/µm2 , only shear rates of 
25 and 100 s-1 could support coagulation. At this lower concentration of TF there there was a 




 Fiber diameters showed that FXI deficient clots had an average of 202 ± 54 nm and NPP 
clots were 134 ± 47 nm. Both NPP and FXI deficient clots displayed the same clot formation rate 
and the same time of about 330 seconds to reach the peak fluorescence before the degradation 
process started. There was a difference in the rate of degradation between NPP and FXI-deficient 
plasma, but these values were not statistically different. The NPP clot had a greater area under 
the curve value than the FXI-deficient clot, which shows that the NPP had a more fibrin than the 
FXI-deficient clot . With the addition of TM, the lag time to fibrin formation was greater in FXI-
deficient plasma compared to NPP. Also the rate of fibrin formation and maximum fibrin were 
much lower in the FXI deficient clots. These studies help to further elucidate the contribution of 
FXI and the contact pathway to flow-dependent coagulation in plasma based systems.  
5.2 Introduction  
Factor XI (FXI) is a 160 kDa glycoprotein that participates in the intrinsic blood 
coagulation pathway and contributes to hemostasis by boosting thrombin generation during clot 
propagation. Activated FXI (FXIa) is a serine protease generated by cleavage of FXI at the 
Arg369-lle370 bond by FXIIa, thrombin or via autocatalytic activation [103]. FXIa contributes to 
sustained thrombin generation via activation of factor IX (FIX) [104]. Individuals with FXI 
deficiencies, also called hemophilia C, appear to be protected against stroke [105] and venous 
thrombosis, but not against myocardial infarction [106]. Studies of Israelis with severe FXI 
deficiency show they have very minor bleeding problems in the heterozygote state, and even in 
most homozygotes with very low levels of the protein [15]. Heterozygotes rarely display a 
bleeding phenotype and spontaneous bleeding is rare.  
The reason why FXI deficiency protects against clots in some types of vessels and not 




possible explanation is that FXI deficiency results in clots that are more susceptible to 
fibrinolysis, especially in vessels known to have high fibrinolytic activity, such as the oral cavity 
and the urinary tract. Subsequent studies extended these observations and showed that reduced 
thrombin generation results in reduced activation of the thrombin-activatable fibrinolysis 
inhibitor (TAFI) [21] and as a result, reduced resistance of clots to fibrinolysis. Animal models 
of thrombosis show that deletion or inhibition of FXI decreases the incidence of occlusive clots 
[109]. However, the mechanisms behind these observations are difficult to ascertain in animal 
models because the type and extent of injury is poorly defined. 
One element of FXI-dependent thrombus growth that has not been studied is the role of 
blood flow, which varies widely throughout the vascular system. The dynamics of fibrin 
polymerization and thrombin generation have been characterized with and without FXI under 
static, or no flow conditions, in closed systems where biochemical reactions can proceed to 
completion. These approaches have been critical for measuring the myriad of factors that 
influence FXI-dependent thrombus growth, however, in vivo, these phenomena are further 
constrained by dilution due to flowing blood. In this study we modified the plasma-based 
microfluidic assay described in Chapter 4. We show that in this assay that below threshold levels 
of TF, FXI-deficiency diminishes thrombin production, which yields clots that are more 
susceptible to fibrinolysis. By adding thrombomodulin (TM) to the system we can discriminate 
the kinetics of fibrin formation at high TF concentrations between normal pooled plasma and 
FXI deficient plasma. In addition, we show that fibrin formed with FXI deficient clots have 




5.3 Materials and methods 
L–α-phosphatidylcholine (PC) and L–α-phosphatidylserine (PS) were purchased from 
Avanti Polar Lipids (Alabaster, AL, USA). Texas red 1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine (DHPE) was purchased from Invitrogen (Carlsbad, CA, USA). Bio-Beads 
SM-2 were purchased from BioRad Laboratories  (Hercules, CA, USA). Sodium deoxycholate 
was purchased from CalBiochem (Gibbstown, NJ, USA). Boc-Val-Pro-Arg-MCA [t-Butyloxyl-
carbonyl-L-Valyl-L-Prolyl-L-Arginine-4-Methyl-Coumaryl-7-Amide] was purchased from 
Peptide Institute Inc. (Osaka, Japan) and a 10 mM stock solution was prepared according to 
manufacturer instruction. Recombinant human tissue factor (TF), IMUBIND tissue factor ELISA 
and D-Dimer ELISA,and Spectrozyme PCa substrate (H-DLys (γ-carbobenzoxy)- Pro-Arg-
pNA.2AcOH) were from America Diagnostica (Stamford, CT), and were used according to the 
manufacturers instructions. Rabbit lung thrombomodulin (TM), human protein C, and human 
thrombin were from Haematologic Technologies Inc. (Essex Junction, VT, USA). Tissue 
Plasminogen activator (tPA) was from Abcam Inc (Cambridge, MA). Normal pooled plasma 
(NPP) and factor II, VIII, IX, X and XI deficient plasmas were purchased from George King 
Biomedical (Overland Park, KS). Alexa Fluor 488 protein labeling kit (Invitrogen, Carlsbad, CA, 
USA) was used to label fibrinogen according to the manufacturers instruction. 
Polydimethylsiloxane (PDMS) (Dow Corning, Sylgard 184) was purchased from Ellsworth 
Adhesives (Germantown, WI). HEPES buffered saline (HBS, 20 mM HEPES, 150 mM CaCl2, 
pH 7.4) was made in house. 3-[(2-Aminoethylamino) propyl] trimethoxysilane  (APTMS), 





5.3.1 Reconstitution of Thrombomodulin into Lipid Vesicles 
TM was reconstituted according previously developed methods [55]. Briefly, lipid 
vesicles were made by drying a mixture of PC, PS and DHPE lipids in a 79:20:1 molar ratio 
under vacuum for 1 hour. The dried lipid film was resuspended and rehydrated in HBS to obtain 
a 2.4 mM lipid vesicle solution. The vesicles were then prepared for TM incorporation by four 
successive freeze/thaw/vortex cycles using liquid nitrogen and a 45 °C water bath. The TM was 
added to the lipid solution to make a final TM concentration of 500 nM, before it was extruded 
21 times through two 200 nm polycarbonate filters.  
5.3.2 Preparation of TF and TM coated silica beads 
The recombinant human TF was incorporated into the liposomes according to the 
protocols used in Chapter 4. TF was also incorporated into PC, PS and DHPE lipids in the same 
ratio as above with the TM and was coated on silica beads as described previously to make beads 
with only TF. For experiments coating both TF and TM on silica beads, the TF was diluted in a 
lipid solution containing lipidated TM while maintaining the same lipid concentration (2.4 mM). 
The zeta potential of the beads was measured using a Zetasizer Nano (Brookhaven instruments 
Corporation). The activity of beads coated with only TF and both TF and TM were quantified by 
measuring the conversion of the thrombin substrate boc-VPR-AMC. The activity of the TM 
beads was quantified using a protein C activation assay as described below. 
5.3.3 Thrombomodulin activity assay 
The activity of the TM on the beads was determined in a well plate reader, using the 
activation of protein C by the thrombin-rabbit lung TM surface bound complex [72]. An 




separate well), 0.1 µM of protein C and 5 nM of thrombin. Activation of the protein C was 
measured after adding the chromogenic substrate Spectrozyme PCa according to the 
manufacturers instructions (absorbance at 405nm).                                                                                                                                                                                                                                                                                 
5.3.4 Stencil fabrication 
To generate the 100 µm circular silica bead features on the glass slides, the assembly of 
the coated silica beads was performed on poly(dimethylsiloxane) (PDMS) stencils. The stencils 
were prepared by spin coating PDMS at 3500 RPM for 40 sec on a flat patterned silicon wafer. 
The wafer contained an array of cylinders 100 µm in diameter and 100 µm in height defined by 
KMPR photoresist. The PDMS was cured at 60 °C for 3 hours, removed from the wafer, and 
then cleaned in acetone and ethanol.  
5.3.5 Convective assembly of silica beads on stencils  
Glass slides were treated with 40% wt APTMS in anhydrous ethanol solution for 45 min. 
The stencils were placed on the glass slide and the silica beads were pipetted onto the stencils. 
Low vacuum was applied and released (~500 mTorr) four times to remove air bubbles that were 
trapped inside the holes of the stencils. The beads in the solution were allowed to settle for 1 hr 
before the excess solution was pipetted of the surface. The assembly was achieved by dragging 
the meniscus of the colloidal suspension droplet over a hydrophilic surface at constant velocity. 
The confinement effect induced by the meniscus coupled with the capillary forces appearing 
between particles during drying led to the formation of a continuous lattice [110]. Finally, the 




5.3.6 Microfluidic plasma flow assay 
A PDMS microfluidic hydrodynamic focusing device (W= 1000 µm, H = 100 µm) was 
vacuum–sealed to the glass slides containing the silica bead patterns. HBS was infused through 
the two side channels to provide the focusing of the plasma, which was perfused through the 
middle channel. The flow rate was set to the desired wall shear rate using: γ = 6 Q/ H2 where γ is 
the shear rate, Q is the volumetric flow rate, W is the width and H is the height. Citrated normal 
pooled plasma (NPP) and FXI deficient plasma were defrosted at 37 °C immediately before the 
flow experiments. Alexa 488-labelled fibrinogen (100:1 plasma fibrinogen: labeled fibrinogen) 
and boc-VPR-AMC (100 µM) were added to the plasma. The citrated plasma was recalcified to 
7.7 mM CaCl2 and perfused through the channel at shear rates of 25, 100, 250 and 500 s-1. For 
lysis experiments, 10 µg/ml of tPA was added to the plasma and perfused through the device for 
20 min. 
5.3.7 Data acquisition and image analysis 
Fibrin deposition and thrombin generation were measured for 10 or 20 min (with or 
without tPA). Images were recorded with epifluorescence microscopy (IX81, Olympus) using a 
40X objective (NA = 0.60). After plasma perfusion, a heparin wash buffer (HBS, 7.5 mM CaCl2, 
1 U/mL heparin) was used to rinse the channel for 5 min at 50 s-1. Six metrics were used to 
quantify the dynamics for the assay; i) Fibrin lag time –defined as the first observable fibrin fiber 
in the image sequence, ii) thrombin lag time- defined as the time to 5% of the maximum 
fluorescence intensity of NPP perfused at 50s-1 over 0.8 molecules-TF/µm 2 , iii) maximum fibrin 
and iv) maximum thrombin- defined as the integrated fluorescence of a 100 µm region-of-




generation rate – defined as the slope between the respective lag times and 95% of the 
maximum.  
5.3.8 Scanning electron microscopy 
Samples for scanning electron microscopy were prepared as previously described [111]. 
Images were taken with JOEL 7000 (Hitachi, Tokyo, Japan) at an accelerating voltage of 1.5 kV 
and a working distance of 6 mm. The diameters of the fibrin fibers were measured in ImageJ. 
The fiber density was measured by averaging the number of fibers that crossed a straight line of 
known distance. Ten lines were drawn per image along with the direction of flow.  
5.3.9 Statistical analysis 
All calculations were performed using Matlab (Natick, MA USA). All data for clot 
formation, structure and fibrinolysis is presented as average ± standard deviation of n = 3-5. For 
comparing results between FXI-deficient plasma and NPP, a Student’s t-test was used to 
determine the differences. Significant differences (p < 0.05) are represented by an asterix (*). 
5.4 Results 
One of our central hypothesis is that FXI-dependent fibrin - thrombin generation and clot 
stability are a shear rate dependent phenomena. Our hypothesis was tested with a plasma based 
microfluidic flow assay in which coagulation was initiated through TF bearing particles at 
different shear rates.  
5.4.1 The effect of shear rate on FXI-dependent thrombin genereation and fibrin deposition 
 NPP and FXI deficient plasma were perfused over 100 µm spots of TF coated silica 




25, 100, 250 and 500 s -1 for 10 min to monitor fibrin deposition and thrombin generation. At 0.8 
molecules-TF/µm2, fibrin deposition decreases with an increase in shear rate both NPP (Fig 
5.1A) and FXI-deficient plasma (Fig 5.1B). There was a sharp transition from the transport 
limited regime at 25 and 100 s-1 to the reaction limited regime at 250 s-1, this same trend was also 
observed in thrombin generation for both NPP and FXI-deficient plasma. There were little or no 
differences between NPP and FXI-deficient plasma based on fluorescence intensity.  
 
 
Figure 5.1. Fibrin and thrombin generation on NPP and FXI def at 0.8 molecules-TF/µm2 . 
Dynamic fibrin and thrombin generation for NPP (A,C) and FXI-deficient plasma (B, D). E. 





At 0.08 molecules-TF/µm2 , only shear rates of 25 and 100 s-1  could support coagulation 
(Fig 5.2 A-D). At this lower concentration of TF there there was a significant diference in 
thrombin generation between NPP and FXI deficient plasma. There was a 75% reduction in 
thrombin generation and a 35% reduction in fibrin deposion for FXI deficient plasma compared 
to NPP. These result suggests that FXI-deficiencies shifts the threshold TF concentration 




Figure 5.2. Fibrin and thrombin generation at 0.08 molecules-TF/µm2. Dynamic fibrin and 





5.4.2 The effect of factor FXI on fibrin morphology  
Although there were not signficant differences in fibrin(ogen) accumulation at high TF 
concentration as measured by epifluorescence, a closer look suggests that the FXI influences 
fibrin fiber morphology (Fig. 5.3). Electron micrographs revealed that the fibers of the FXI-
deficient clots were 36% thicker than NPP fibers, with FXI deficient clots having an average of 
202 ± 54 nm and NPP clots were 134 ± 47 nm (Fig. 5.3). 
 
           
 
 
Figure 5.3. SEM images of clots formed with A) NPP or B) FXI deficient plasma. 




There is a higher fiber density in the clots formed with the NPP compared to that of FXI 
deficient plasma, especially at the periphery of the clots. Furthermore, the clots formed with the 
FXI-deficient plasma appear to have larger pore spaces than the NPP clots. These thicker fibers 
and more porous fibrin gels formed in the abence of FXI would likely lyse faster than those 
formed with FXI.  
 5.4.3 Fibrinolysis in clots formed under flow can distinguish controls from FXI deficient 
plasma 
To incorporate fibrinolysis into the coagulation process, fibrin generation in the presence 
of tPA in the plasma perfused over 0.8 molecules-TF/µm2 for 20 minutes at 25 s-1. In this assay, 
fibrin polymerization competes with fibrinolysis, which is detected as a decrease in the 
fluorescence intesity (Fig. 5.4A).   
 
 
Figure 5.4. Fibrinolysis of clots formed for NPP and FXI deficient plasma under flow at 25 s-
1. (A) Representative fibrin deposition and lysis curves for NPP and FXI deficient clots (B) 




Both NPP and FXI deficient clots displayed the same clot formation rate and the same 
time of about 330 seconds to reach the peak fluorescence before the degradation process started. 
There was a difference in the rate of degradation between NPP and FXI-deficient plasma, but 
this value were not statistically different. The NPP clot had a greater area under the curve value 
than the FXI-deficient clot, which shows that the NPP had a more fibrin than the FXI-deficient 
clot (Fig. 5.4C) 
5.5.4 Addition of thrombomodulin further differentiates NPP from FXI deficient plasma  
The results above show that by decreasing the TF concentration from 0.8 molecules-
TF/µm2 to 0.08 molecules-TF/µm2, a decrease in coagulation is achieved, which may lead to a 
tighter discrimination between NPP and FXI-deficient plasma. We incorporated the protein C 
and protein S pathway into our microfluidic flow assays by adding lipidated-thrombomodulin 
(TM) to test whether the endothelial cell mediated anticoagulation pathway could further 
discriminate NPP and FXI-deficient plasma. We perfused the NPP and FXI-deficient plasma 
over lipidated-TF-TM beads at a TF concentration of 0.8 molecules-TF/µm2 and a TM 
concentration of 50 nM (2.3 ✕ 10-7) mol/µm2) at a shear rate of 25 s-1 for 10 min.  
There was a dramatic decrease in coagulation with the addition of TM in both NPP and 
FXI-deficient plasma (Fig 5.5). However, the decrease in fibrin formation generated with FXI-
deficient plasma was greater than the decrease in fibrin generation in NPP gels. Thus, by 
incorporating TM into the assay we were able to differentiate between clots formed with NPP 
and FXI deficient plasma even at high TF. With the addition of TM, the lag time to fibrin 
formation was greater in FXI-deficient plasma compared to NPP. Also the rate of fibrin 







In this study, we describe and build on a plasma-based assay for measuring thrombin 
generation and fibrin deposition in vitro [31]. The assay uses silica beads coated with TF 
containing lipid bilayers to simulate the presence of TF bearing cells or micro particles. We used 
this plasma-based assay to qualitatively and quantitatively differentiate between clots formed 
Figure 5.5. Addition of thrombomodulin to NPP and FXI deficient plasma shows less fibrin 
deposition A) Fluorescence images of fibrin clots formed for NPP and FXI-deficient plasma 
with and without TM. B) Fibrin lag time C) Deposition rate D) Maximum fibrin in NPP and 




from normal pooled plasma (NPP) and FXI-deficient plasma under flow conditions. We found 
that in our assays we can discriminate between NPP and FXI-deficient plasma by visualizing 
fibrin and thrombin deposition in real time, analyzing fiber morphology and measuring lysis rate. 
At high TF concentrations there was no significant difference in the kinetics of fibrin 
accumulation and thrombin generation. At lower TF concentrations, there was a slight increase 
in thrombin generation in NPP compared to the FXI deficient plasma. At high TF concentrations 
it seems that FXI contributes minimally to thrombin generation. However, at lower TF 
concentrations, the rate of activation of prothrombin is modest enough that the FXI contribution 
to thrombin generation can be observed experimentally. At high TF concentrations we were able 
to observe differences in the morphology of clots made with NPP compared to FXI-deficient 
plasma. The electron micrographs images of fibrin fibers revealed that FXI-deficient fibers were 
larger, had a lower density, and had larger pore spaces. We also observed that when we added 
tPA to the NPP and the FXI-deficient plasma, the FXI-deficient gels had lower peak fibrin 
fluorescence and a smaller area-under-the-curve (AUC). These results agree with the studies that 
have shown that thicker fibers lyse faster [34]. Previous work has also shown that thrombin-
mediated activation of FXI results in a thrombin activatable fibrinolysis inhibitor (TAFI)-
dependent inhibition of fibrinolysis and reduced plasma procoagulant activity results in less 
TAFI activation and increased fibrinolysis [36].  
TM decreases procoagulant activity through the protein C pathway [102]. The addition of 
TM further discriminates NPP and FXI-deficient plasmas even at high TF concentrations. In 
NPP, TM decreases the fibrin formation by about 80%, and in FXI deficient plasma, about 95%. 
It is unclear whether the TM is effectively dampening TF-dependent thrombin generation, and 




generation by some unknown mechanism. Regardless, the integration of surface bound TM into 
our plasma based assay will allow for future studies on the interplay between TF-mediated 
coagulation and the APC anticoagulation pathway. In future studies we will determine whether 
this assay can discriminate bleeders and non-bleeders with severe FXI deficiencies.  
We expect that this assay can be further improved by the addition of collagen to the 
procoagulant surface so that the effects of platelets attaching to a growing clot at different 
coagulation kinetics can be studied with and without FXI present in the system. Additionally, as 
collagen has been shown to contribute to coagulation by activating FXII [22], which directly 
activates FXI in the contact pathway of coagulation, these additional studies could further 
elucidate the contribution of FXI and the contact pathway to flow-dependent coagulation in 
whole blood.  
5.6 Conclusion 
In conclusion we have modified a plasma-based flow assay for measuring thrombin 
generation and fibrin deposition to include the APC pathway and fibrinolysis. We have shown at 
high TF concentrations there is no difference in cumulative fibrin and thrombin generation 
kinetics measured by fluorescence between NPP and FXI-deficient plasma. There is a significant 
differece at low TF. However, even at high concentrations of TF we show that FXI-deficient 
plasma produces fibrin gels with fibers that are larger in diameter and larger pores than gel 
derived from NPP. Additionally, we show that by adding surface bound TM to the system, we 
can discriminate between the fibrin and thrombin generation kinetics both qualitatively and 






6.1 Summary of Results 
Coagulation is initiated when an injury exposes wall bound tissue factor to flowing blood. 
Not only do anticoagulant pathways kinetically limit coagulation, but coagulation is also 
regulated by mass transfer limitations associated with the transport of the zymogens to and the 
enzymes away from the injury site. In this thesis work, in vitro microfluidic vascular injury were 
used to capture the dynamics of blood flow while offering low volume requirements.  
Chapter 3 described a whole blood system that incorporated blood flow, platelet activity 
and coagulation in one assay. Whole blood from a cohort of individuals with a wide range of 
FVIII levels (<1% to 26 %) was perfused in microfluidic flow assays over collagen-TF substrates 
at venous flow conditions (100 s-1). Thrombin generation was calculated with a computational 
spatial-temporal model of thrombus formation. Mild FVIII deficiencies (5-30% normal levels) 
could support fibrin fiber formation, while severe (<1%) and moderate (1-5%) deficiencies could 
not. Based on these experimental observations, computational calculations estimate an average 
thrombin concentration of ~10 nM is necessary to support fibrin formation under flow. There 
was no difference in fibrin formation between the severe and moderate deficiencies, but platelet 
aggregate size was significantly larger for moderate deficiencies. Computational calculations 
estimate that the local thrombin concentration in moderate deficiencies is high enough to induce 
platelet activation (>1 nM), but too low to support fibrin formation (>10 nM). In the absence of 
platelets, fibrin formation was not supported even at normal FVIII levels, suggesting platelet 
adhesion is necessary for fibrin formation. Individuals treated by replacement therapy, 




recombinant FVIIa, had a reduced lag time in fibrin formation, as well as elevated fibrin 
accumulation compared to healthy controls. Treatment of FVIIa, but not FVIII, resulted in 
significant changes in fibrin dynamics that could lead to a prothrombotic state. 
In Chapter 4 we developed a plasma based microfluidic flow assay for measuring 
thrombin generation and fibrin deposition. This method has some advantages over whole blood 
assays, including eliminating the variability in platelet function and allowing for the use of 
frozen plasmas as opposed to freshly drawn blood. The assay uses silica beads coated with a TF 
containing lipid bilayer to simulate the presentation of adherent TF-bearing microparticles. TF-
coated silica beads (~800 nm) were patterned into 18-85 µm spots. Normal pooled plasma and 
factors VIII, IX and XI deficient plasmas were perfused over beads coated with 0.08, 0.8 and 8 
molecules-TF/µm2. We showed that there was a threshold spot size for fibrin formation and a 
shear rate dependent TF concentration that was necessary to support fibrin polymerization. FVIII 
and FIX had minor effects on fibrin dynamics at 8 molecules-TF/ µm2, but were essential at 0.8 
molecules-TF/µm2. These results show that fibrin deposition requires perturbations in the flow 
field that protect reactions from dilution by flow under venous and arterial conditions. FVIII and 
FIX have a modest effect on fibrin deposition at high TF concentration, but are necessary for 
fibrin deposition at low concentrations. FXI amplifies thrombin generation under flow at both 
low and high TF concentrations.  
In Chapter 5 we used the plasma-based system to investigate the role of FXI deficiency 
on clot propagation. We show that in this assay that at lower levels of TF, below 0.8 molecules-
TF/µm2, FXI-deficiency diminishes thrombin production, which yields clots that are more 
susceptible to fibrinolysis. By adding thrombomodulin (TM) to the system we can discriminate 




FXI deficient plasma. In addition, we show that fibrin formed with FXI deficient clots have 
differences in fiber size, density and pore size compared to normal pooled plasma.  
6.2 Future Research  
Following the present work, we are looking forward to improving the performance of the 
plasma based microfluidic flow assay and also to show that FXI inhibition is protective against 
occlusion in the presence of collagen with low concentrations of TF. Some of the future 
experiments to be conducted are outlined below. 
6.2.1 The relative role of FXI and TF on propagating a clot in a whole blood system 
In both whole blood and plasma we have shown that there exists a threshold surface 
concentration that is required to trigger coagulation that is unique for each wall shear rate. The 
hypothesis of this study is that FXI deficiency will decrease platelet and fibrin accumulation at or 
below this threshold concentration, but above this concentration thrombin production via TF will 
overwhelm the effect of FXI. These experiments should be performed using reconstituted blood 
in normal pooled plasma (NPP) of plasma deficient in FXI at a constant platelet count 
(450,000/mL) and hematocrit (0.5). Reconstituted blood consists of freshly isolated platelet and 
erythrocytes mixed with plasma. The blood will be perfused at wall shear rates of 100, 200, 400, 
800, and 1600 s-1 to cover the physiological range. The data collected will be the number of 
platelets adhering to the density of fibrin on the collagen-TF strip as a function of time and wall 
shear rate. From this data, we will calculate rate of adhesion (number of platelets adhered/time), 






6.2.2. FXI inhibition to reduce occlusive clots 
To form an occlusive clot in the MFA the assay should be run at constant pressure, as 
opposed to constant flow rate. At constant flow pressures of 10-20 mmHg, we have found that 
thrombi from whole blood perfused over collagen and collagen-TF surfaces can occlude 
microfluidic channels (~100 µn) in a period of 5-10 min. In this study, the time to occlusion 
should be measured in the presence of increasing concentration (0-5 mg/mL) of a FXI inhibiting 
monoclonal antibody. The dose-response of the FXI antibody using whole blood from healthy 
donors should also be investigated. 100 nm tracer particles should be added to the blood to 
measure velocity and occlusion time. Following the experiment, the clots should be fixed, 
stained for fibrin and platelets, and imaged by confocal microscopy to determine differences in 
volume and clot structure. 
6.2.3. Reversibility of FXI inhibition by antifibrinolytic agents. 
A desired feature of any anticoagulant is reversibility. For instance, protamine sulfate, a 
cationic peptide, reverses the anticoagulant effects of heparin. This is considered one of the 
major advantages of heparin. In this study the effect of two common antifibrinolytic agents, ε-
aminocaproic acid (EACA) and transaxemic acid (TXA) should be studied on reversing the 
inhibitory effect of FXI deficiency. The same metrics described above to determine half-
maximal effective concentration (EC50) values of each of these agents should be measured. 
 Accomplishment of this study is expected to demonstrate the effectiveness of FXI 
inhibition as a potential anticoagulation strategy for venous thrombosis. That, in turn, is expected 
to set the scene for translational studies using FXI inhibition using novel peptide and small 




coagulation is responsible for clot propagation, as opposed to clot initiation, which is likely 
catalyzed by the extrinsic, or TF, pathway. This is important because it may provide motivation 
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Supporting Video Legends 
Supplementary Video 1- Platelet (blue) and fibrin (green) accumulation from a normal control 
on collagen-TF surface at 100 s-1. The direction of flow is from top to bottom.  
Supplementary Video 2- Platelet (blue) and fibrin (green) accumulation from an individual with 
mild hemophilia (FVIII:C = 11.1%) on collagen-TF surface at 100 s-1.  
Supplementary Video 3-Platelet (blue) and fibrin (green) accumulation from an individual with 
moderate hemophilia (FVIII:C = 3.1%) on collagen-TF surface at 100 s-1.  
Supplementary Video 4-Platelet (blue) and fibrin (green) accumulation from an individual with 
severe hemophilia (FVIII:C = 0.4%) on collagen-TF surface at 100 s-1.  
 
 
Figure B.1. Sensitivity of fibrin deposition to tissue factor surface concentration. (A) 
Fibrin density as measured by integrated fluorescence resulting from perfusions of normal 
whole blood at 100 s-1 for 5 min over surfaces with varying surface TF concentrations. (B) D-
Dimer levels from plasmin digested thrombi formed at 100 s-1 for 5 min over surfaces with 






Figure B.2. Thrombin generation under flow in FVIII deficiencies. The cumulative 
thrombin production was calculated using a spatial-temporal computational model of 
thrombus formation on 2.3 fmol TF/cm2. All data is normalized by the maximum cumulative 
thrombin production for 100% FVIII. (A) Normalized cumulative thrombin as a function of 
time for FVIII levels of 1, 5, 10, 20, and 100%. The dynamics of thrombin generation were 
quantified by three metrics: (B) Maximum cumulative thrombin production, which is the total 
thrombin produced at the end of the 5 min. simulation. (C) The lag time, which is the time to 
10% of the maximum cumulative thrombin production for 100% FVIII. (D) The velocity, 
which is the slope of the cumulative thrombin curve from the lag time to the end of the 
simulation. Each data point () represents a single simulation. The lines are extrapolations 








Figure B.3. The relative roles of intrinsic and extrinsic tenase on Xa generation in 
response to rFVIIa treatment. The total cumulative Xa production for different plasma 
levels of FVIIa (A) and the relative contribution from intrinsic (FVIIIa:IXa) tenase (B) and 
extrinsic (TF:FVIIa) tenase (C). Xa production is normalized by the total cumulative 










Figure C.1. Microblotting procedure for patterning bead spots. Silica beads were 
synthesized and then treated with peroxide to yield a hydroxyl rich hydrophilic surface. TF 
containing liposomes spontaneously rupture on the beads and form stable bilayers in the 
presence of CaCl2. TF-coated beads have a net negative charge which provides an electrostatic 
interaction with positively charged APTMS functionalized glass. Beads were selectively 
removed from the glass by a polydimethylsiloxane (PDMS) microblot containing 20, 50 or 100 
µm holes that were placed on the adsorbed beads while immersed in HBS and carefully 
removed. In areas where the PDMS came in contact with the beads, the beads were removed 








Figure C.2. TF activity measured by thrombin generation. Activity of TF coated silica beads 
measured by the kinetics of conversion of the thrombin substrate boc-VPR-AMC. Fractional 
conversion of the substrate was determined by: C = (F – Fmin)/(Fmax – Fmin), where C is the 
fractional conversion, F is the instantaneous fluorescence at any time, Fmin is the minimum 
fluorescence for that well, and Fmax is the maximum fluorescence in that well during the 
experiment. The initiation time was defined as the time when C is equal to or greater than 0.05.  
 
 
Figure C.5. D-dimer measurement of cumulative fibrin deposition. Following an assay, 






Figure C.3. Fibrin deposition on 300 nm and 800 nm TF-coated beads and micropatterned TF 
bilayers. NPP was perfused over at a wall shear rate of 50 s-1 and 8 molecules-TF/µm2 on the 300 







Figure C.4. Whole blood flow assay on TF-beads. Whole blood was perfused over bead spots 
with diameters of 85±6 µm (A), 44±4 µm (B) and 18±4 µm (C) at a wall shear rate of 50 s-1 and 








Figure C.6. Fibrin deposition and thrombin generation as a function of position. NPP was 
perfused over spots at 50, 100, 250, 500 and 100 s-1 and 8 molecules-TF/µm2. The data was 
normalized by the maximum integrated fluorescence intensity at 50 s-1 on the spot at x = 800 µm 
and presented in relative fluorescence units (RFU). Data are average and SD (n=3). 
 
Figure C.7. Relationship between fluorescence intensity and fibrinogen concentration. (A) 
Standard curve of fluorescence versus fibrinogen concentration. Fibrinogen solutions of 1-25 
mg/mL (1:100 Alexa-488 labeled fibrinogen:unlabeled fibrinogen) filled a microfluidic channel 
with a height of 15 µm. The integrated fluorescence intensity of a 100 µm spot was measured to 
correspond to the 100 µm region-of-interest used to analyze flow experiments over patterned 
beads. Equation represents the least squares fit of the data. (B) Calculated fibrin(ogen) density 
within fibrin gels formed on 8 molecules-TF/µm2 as function of shear rate based on the standard 







Copyright Information for published manuscripts 
 
This section contains the copyright information for the chapters that are reproduced from 
different published manuscripts in journals 
B.1  Copyright Information for Journal of Thrombosis and Haemostasis JTH (Chapter 4) 
License Number 3346550654516 
License date Mar 12, 2014 
Licensed content publisher John Wiley and Sons 
Licensed content publication Journal of Thrombosis and Haemostasis 
Licensed content title Thrombin generation and fibrin formation under flow on biomimetic 
tissue factor-rich surfaces 
Licensed copyright line © 2013 International Society on Thrombosis and Haemostasis 
Licensed content author A. A. Onasoga-Jarvis,T. J. Puls,S. K. O'Brien,L. Kuang,H. J. Liang,K. 
B. Neeves 
Licensed content date Mar 5, 2014 
Start page 373 
End page 382 
Type of use Dissertation/Thesis 
Requestor type Author of this Wiley article 
Format Print and electronic 
Portion Full article 
Will you be translating? No 
Title of your thesis / 
dissertation 
Mass transfer limitations of blood clot formation on tissue factor and 
its role in the pathophysiology of hemophilia A and C 
Expected completion date Apr 2014 
Expected size (number of 
pages) 
120 
